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It is now well established that chemotherapy-induced reduction in tumor load is a 
function of apoptotic cell death, orchestrated by intracellular caspase proteases.  
However, the effectiveness of some of these therapies is blunted by mutations 
affecting specific effectors genes controlling and/or regulating apoptotic signaling. 
Therefore, there has been a surge of activity around identification of novel pathways 
of cell death, which could function in tandem with or in the absence of efficient 
apoptotic machinery.  In this regard, recent evidence has highlighted the existence of 
a novel, caspase-independent cell death pathway, termed autophagy, which is 
activated in response to growth factor deprivation or upon exposure to genotoxic 
compounds. It should be noted that autophagy has been described as a cell survival 
mechanism as well as a death execution pathway. Using a novel small molecule 1,3-
dibutyl-2-thiooxo-imidazolidine-4,5-dione (C1), which is a strong inducer of 
intracellular hydrogen peroxide (H2O2), this work demonstrated the simultaneous 
induction of non-canonical autophagy and apoptotic cell death in human colorectal 
carcinoma cells. It was later discovered that the ability of C1 to induce autophagy is 
not limited to a single cell line. Of importance, this study supported the existence of 
non-canonical autophagy induced by C1. Whereas, silencing of the integral mediator 
of autophagy, beclin1 did not provide protection against autophagy or cell death, Atg 
7 or Ulk1 knock-down significantly abrogated C1-induced autophagy. In the current 
study, the induction of autophagy and apoptosis was found to be mutually exclusive. 
Despite this fact, early H2O2 production was critical in controlling the induction of 
autophagy and apoptosis via activation of extracellular regulated kinase (ERK) and c-
Jun N-terminal kinase (JNK). Inhibition of ERK and JNK virtually completely 
 xii
blocked drug-induced autophagy and apoptosis. Interestingly, inhibition of JNK 
activity reversed C1-induced increase in Atg7 expression, indicating that JNK may 
regulate the autophagic pathway by activating Atg7. On the other hand, this study also 
uncovered a novel role of ERK in mediating p53 suppression which is integral in the 
induction of autophagy. This work implicates ERK and JNK in the induction of non-
canonical autophagy and apoptotic cell death by a small molecule compound, and 
underscores the plausibility of these proteins as targets in cancer therapy. In particular, 
the ability of ERK inhibitor to attenuate cell death in metastatic and highly malignant 
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PART I:  PROGRAMMED CELL DEATH  
Programmed cell death  (PCD) was discovered in the 19th century, first 
described during amphibian metamorphosis (Reviewed in (Jacobson et al., 1997). 
Since its discovery, tremendous progress has been made in understanding PCD. To 
date, PCD has been linked to various physiological and pathological states. Its 
definition has also been modified to refer to any form of cell death that is mediated 
by an intracellular death program (Jacobson et al., 1997). Therefore, though 
apoptosis represents a well established form of cell death, other cell death pathways 
have gained prominent interest over the years. These non-apoptotic cell death 
pathways include necrosis, autophagy and mitotic catastrophe. 
 
1.1 Necrosis 
 Necrosis has been viewed as a passive, uncontrolled and accidental form of 
cell death. Recent advancements in the field, however, propagated the notion that 
necrosis is a more defined and well controlled cell death. Necrotic cell death is 
characterized by several morphological distinctions, such as cytoplasmic swelling 
and loss of plasma membrane integrity (Zong and Thompson, 2006). Accompanying 
these necrotic phenotypes include biochemical alterations in terms of mitochondrial 
depolarization, activation of DNA repair protein poly (ADP-ribose) polymerase 
(PARP) and intracellular production of reactive oxygen species (ROS) (Zong and 
Thompson, 2006). 
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 Identification of key molecular players in the regulation of necrosis has 
unravelled the complexity and intricacy of the programmed necrotic network. In 
many experimental systems, exposure of cells to tumor necrosis factor- α (TNF-α) 
culminates in necrotic phenotypes only in the background of caspase inhibition 
(Grooten et al., 1993; Vercammen et al., 1998). Moreover, the presence of the pan-
caspase inhibitor, benzyoxycarbonyl valanyl alanyl-fluoromethylketone (zVAD-fmk) 
invariably potentiates the necrotic death pathway, indicating that necrosis serves as a 
back up death effector mechanism in the event of caspase inhibition or deficiency 
(Vercammen et al., 1998). Loss of function experiments of receptor interacting 
protein 1 (RIP1) have also confirmed the role of RIP1 as a central initiator of 
necrosis (Harper et al., 2003; Holler et al., 2000). In addition, it was discovered that 
full length RIP1 is essential in the induction of necrosis, while cleaved fragment of 
RIP1 by caspase-8 sensitizes the cells to apoptosis (Lin et al., 1999). These results 
placed RIP1 at the cross-road of apoptotic and necrotic signaling, indicating that 
RIP1 is a key molecule in mediating the cross-talk between these two prominent cell 
death pathways. 
 Stimulation of cells with excessive amount of ROS is invariably linked to 
necrotic cell death. ROS mediates cellular damage such as lipid oxidation or DNA 
damage, and is also capable of promoting necrotic influx of calcium (Ca2+), further 
potentiating the necrotic response (Golstein and Kroemer, 2007; Morgan et al., 
2008). DNA damage due to excessive ROS trigger may lead to hyperactivation of 
PARP, and in this process β-nicotinamide adenine dinucleotide (NAD), the substrate 
for poly(ADP-ribosyl)ation is depleted (van Wijk and Hageman, 2005). 
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Concomitantly, cellular adenosine triphosphate (ATP) level is depleted, as aerobic 
glycolysis is dependent on NAD (D'Amours et al., 1999). In relation to this, massive 
Ca2+ influx could also lead to enhanced nitric oxide synthase (NOS) activity 
(Dawson et al., 1991), as well as activating intracellular phospholipases and 
proteases (Festjens et al., 2006), invoking damage to cellular constituents and 
compromising membrane integrity.  
   
1.2 Mitotic Catastrophe 
 Strictly speaking, mitotic catastrophe could not be categorized as a form of 
cell death; rather, it represents an irreversible trigger for cell death. Morphologically, 
mitotic catastrophe is characterized by enlarged cells, multiple micronuclei and 
decondensed chromatin (Roninson et al., 2001; Swanson et al., 1995). Mitotic 
catastrophe is a result of aberrant chromosome segregation, culminating in the failure 
to undergo mitosis (Castedo et al., 2004a). Accordingly, mitotic catastrophe is 
frequently induced by chemotherapeutic agents such as vincristine and daunorubicin, 
causing DNA damage and deranged spindle formation (Castedo et al., 2004b). 
Certainly, inability of the cells to activate proper DNA damage check points and 
ensuing DNA repair mechanisms contribute to the culmination of mitotic 
catastrophe. This is particularly relevant to cancer cells as they generally exhibit 
deficiencies in cell cycle check point control.  
 It is thus unsurprising that the cell cycle regulators and kinases have been 
implicated in mitotic catastrophe. The Cdk1/cyclin B1 complex activation is 
necessary for cell cycle progression from G2 to M phase and their degradation by 
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anaphase promoting complex (APC) is essential for progression into anaphase (Nigg, 
2001). Premature entry of active Cdk1/cyclin B1 complex into the nucleus has been 
found to be associated with premature chromatin condensation (Fotedar et al., 1995; 
Porter et al., 2003). Indeed, various cases of mitotic catastrophe were linked to an 
increase in nuclear cyclin B1 (Chan et al., 1999; Yoshikawa et al., 2001).  
 In human cells, checkpoint kinase 2 (Chk2) was found to be a major protector 
from mitotic catastrophe. Inhibition of Chk2 facilitated the induction of mitotic 
catastrophe and sensitized cancer cells to apoptosis (Castedo et al., 2004c). The 
negative regulator of caspase-dependent apoptosis, survivin has also been implicated 
in mitotic catastrophe. Survivin was found to be a substrate of Cdk1 as well as a 
binding partner of aurora B kinase (Bolton et al., 2002). Survivin-Aurora B complex 
is essential for the spindle assembly checkpoint by overseeing the chromosome 
segregation process (Lens and Medema, 2003).  
 
1.3 Apoptosis 
Apoptosis represents one of the most prominent PCD pathways and it was 
first described in the 1970s to illustrate a specific type of cell death which occurs 
during normal development and tissue homeostasis (Kerr et al., 1972). Apoptosis has 
since been discovered as an essential component in various physiological functions 
such as embryonic development and immunity (Zimmermann et al., 2001). The 
elimination of unwanted cells by apoptosis serves important functions, which 
includes sculpting structures, deletion of unwanted structures, control of cell 
numbers, removal of harmful or damaged cells and production of differentiated cells 
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(Jacobson et al., 1997). Therefore, deregulation of apoptosis has been linked to 
various disease pathologies, including neurodegenerative diseases, autoimmunity and 
cancer (Okada and Mak, 2004). Cells undergoing apoptosis frequently display 
classical morphological characteristics such as cellular shrinkage, chromatin 
condensation, DNA fragmentation and membrane blebbing (Kerr et al., 1972). In 
addition, apoptosizing cells usually form apoptotic bodies which are rapidly 
phagocytosed by neighboring macrophages without eliciting an inflammatory 
response (Jacobson et al., 1997).   
 
1.3.1 Molecular mechanisms of apoptosis 
 The remarkably uniform morphological and biochemical hallmarks of 
apoptotic cell death across tissues and animal models suggest an existence of a highly 
regulated and controlled cell death programme within the cell. Central to the 
apoptotic mechanisms are a group of cysteine proteases called caspases, which are 
the principle executioners of apoptotic cell death. Caspases are high specificity 
proteases, cleaving substrates with tetra- or pentapeptide recognition sequences at the 
aspartic residues (Green and Evan, 2002). To avoid detrimental effects to the cell, 
caspases are synthesized as inactive zymogens called pro-caspases, which undergo 
proteolytic cleavage to form mature proteases. In mammalian cells, caspases are 
divided into two major groups. The first being the ‘initiator’ caspases, exemplified by 
caspases 8 and 9, are being activated via oligomerization and autoactivation in 
response to upstream death signals. The ‘executioner’ caspases, such as caspases 3, 6 
and 7 are being activated by the initiator caspases by proteolytic cleavage. The 
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executioner caspases, in turn, cleave other downstream substrates and their activation 
is largely responsible for most of the morphological hallmarks associated with 
apoptosis. One of the well described substrate of caspase 3 is the nuclease inhibitor 
inhibitor of caspase-activated Dnase (iCAD). Cleavage and inactivation of iCAD by 
caspase 3 results in the liberation of caspase activated Dnase (CAD) and ultimately 
leads to DNA fragmentation (Enari et al., 1998). The effector caspases also mediate 
the membrane blebbing phenomenon by activating several adaptor proteins such as 
Rho-associated kinase 1 (ROCK1), p-21 activated kinase (PAK) and gelsolin. 
(Coleman et al., 2001; Kothakota et al., 1997; Rudel and Bokoch, 1997) 
 
1.3.2 Extrinsic and intrinsic apoptotic pathways 
 Apoptotic cascade is mediated through two major pathways of apoptosis, 
namely the extrinsic and intrinsic cell death pathways. The extrinsic pathway is 
engaged by ligation of death ligands to the cell surface death receptors. Some ligands 
which have been identified to date include Fas ligand, TNF-related apoptosis 
inducing factor (TRAIL) and TNF, which binds to specific death receptors such as 
FAS, TNF Receptor (TNF R) and Death Receptors 4 (DR4) and 5 (DR5) 
(Thornberry and Lazebnik, 1998). Efficient ligand and receptor binding mediates the 
activation of Death Inducing Signaling Complex (DISC), via the recruitment of the 
adaptor protein Fas-associated death domain-containing protein (FADD) to the 
cytoplasmic tail of the death receptors (Budihardjo et al., 1999). FADD connects 
caspase 8 to the DISC through interaction of their respective death- effector domain 
 7
(DED). The induced proximity of caspase 8 molecules resulted in their autoactivation 
(Hengartner, 2000). 
 BH3 interacting domain death agonist (Bid), a BH3 domain containing 
member of the B-cell lymphoma protein 2 (Bcl-2) family, transmits the death signals 
from the extrinsic pathway to the intrinsic pathway of apoptosis. Bid can be cleaved 
by caspase 8 to form truncated Bid (t-Bid), which then translocates to the 
mitochondria to elicit mitochondrial outer membrane permeabilization (MOMP) (Li 
et al., 1998). Effects of t-Bid on the mitochondria are predominantly due to its ability 
to activate pro-apoptotic Bcl-2 family members Bcl-2 associated X protein (Bax) and 
Bcl-2 antagonist/killer (Bak), leading to their oligomerization on the mitochondrial 
membrane (Korsmeyer et al., 2000). These signals mediate the release of a critical 
apoptogenic factor, cytochrome c from the mitochondria to the cytosol (Wei et al., 
2001). An array of biochemical events eventually leads to the formation of a large 
holoenzyme, apoptosome, which comprises of cytochrome c, dATP, apoptotic 
protease activating factor-1 (Apaf-1) and caspase 9. Association of caspase 9 with the 
apoptosome leads to its activation by mean of conformational change (Rodriguez and 
Lazebnik, 1999). Notably, catalytic processing of caspase 9 does not determine its 
activity, unlike other caspases (Stennicke et al., 1999).  
 The interaction between Bcl-2 family members governs the mitochondrial 
death signals. Based on structural and functional similarities, the Bcl-2 family 
members are divided into three classes. Class I consists of anti-apoptotic proteins 
such as Bcl-2, Bcl-xL, Bcl-w and Mcl-1. Class II and III contains pro-apoptotic 
members, including Bax and Bak (Adams and Cory, 1998). Apart from neutralizing 
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the actions of anti-apoptotic Bcl-2 family members, Bax and Bak could also form 
heterodimers, which interacts with the mitochondrial permeability transition pore 
(PTP) to induce cytochrome c release. The anti-apoptotic Bcl-2 and Bcl-xL block 
cytochrome c release by either binding directly to one of the subunits of the PTP, 
Voltage dependent anion channel (VDAC) or heterodimerize with Bax or Bak 
(Narita et al., 1998; Shimizu et al., 1999). 
 The existence of caspase-independent pathway in apoptosis reveals the 
importance of apoptotic regulation in cellular homeostasis. One of the key regulators 
of caspase-independent pathway is endonuclease G (endoG), which is a 
mitochondrial specific nuclease responsible for chromatin DNA fragmentation (Li et 
al., 2001). Similar to cytochrome c, second mitochondrial activator of caspases/ 
direct IAP-binding protein with low pI (SMAC/DIABLO) is also a potent 
apoptogenic factor which is released from the mitochondria to the cytosol upon 
induction of apoptosis. Pro-apoptotic activity of SMAC is mainly due to its 
inhibitory effect on inhibitor of apoptosis (IAP), preventing IAP from inactivating 
caspase 9 (Du et al., 2000). In addition, apoptosis inducing factor (AIF) could also 
translocate from the mitochondria to the nucleus during apoptosis induction. The 
action of AIF is independent of caspase activation and could trigger DNA 




                  
 
Figure 1: Two major apoptotic death signaling pathways in the cell. The 
extrinsic death pathway is exemplified by binding of CD95 ligand to CD95 death 
receptor, while the intrinsic or mitochondrial apoptotic signaling is usually a result of 
cellular insults such as DNA damage. The two pathways are interlinked by Bid, 
which could be cleaved by caspase-8 and subsequently promote mitochondrial 








1.3.3 Apoptosis: A barrier to cancer 
 Acquired resistance to apoptosis represents a hallmark of most, if not all types 
of cancer. The discovery of Bcl-2 as a proto-oncogene further associates evasion of 
apoptosis to tumorigenesis. Various studies have lent support to this hypothesis. Bcl-
2 is upregulated in follicular lymphoma following chromosomal translocation 
(Tsujimoto et al., 1987). In addition, overexpression of Bcl-2 prevents apoptotic cell 
death in hematopoietic cell lines following growth factor withdrawal (Vaux et al., 
1988). High Bcl-2 level confers growth advantage to human B and T lymphoblasts 
(Tsujimoto, 1989). Moreover, mice overexpressing both Bcl-2 and v-myc 
myelocytomatosis viral oncogene homolog (avian) (myc) develop tumors much 
faster than myc-overexpressing mice alone (Strasser et al., 1990). It is now clear that 
instead of driving cell proliferation, Bcl-2 exerts its pro-survival effects by 
abrogating cell death responses (Johnstone et al., 2002). 
 The importance of apoptosis in circumventing tumor growth is further 
substantiated with the discovery of p53. Mutation of the tumor suppressor gene, p53 
results in loss of p53 protein in more than 50% of human cancers (Harris, 1996). To 
this end, p53 has been recognized as the ‘guardian of the genome’ as it plays a vital 
role in the regulation of cell cycle and apoptosis. p53 directly mediates apoptotic 
response in abnormally proliferating cells or damaged cells. The ability of p53 to 
transcriptionally activate an array of apoptotic genes contribute to its pro-apoptotic 
role. These ‘p53-inducible genes’ (PIGS) include APAF1, BAX, FAS, NOXA and 
p53-upregulated mediator of apoptosis (PUMA) (Polyak et al., 1997; Yu et al., 1999; 
Zhao et al., 2000). In addition, a transcriptionally independent role of p53 in 
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apoptosis has also been documented, which involves subcellular localization of p53 
and its association with apoptotic proteins such as Bax and PUMA (Chipuk et al., 
2008; Chipuk and Green, 2004; Schuler and Green, 2001) 
    
1.4 Autophagy 
 
1.4.1 Role of autophagy in human physiology and pathology 
 Evolutionarily, autophagy is a bulk degradation process which is highly 
conserved among eukaryotes. Since its discovery back in the 1960s, autophagy has 
been regarded as a non-selective cellular clearance mechanism. Nonetheless, interest 
in autophagy research has increased tremendously since a decade ago, and many 
important findings have been discovered in relation to autophagy in health and 
diseases. 
 Coined by Christian de Duve, who pioneers on lysosomal work, autophagy 
literally means ‘self-eating’ whereby cellular constituents and damaged organelles 
are being degraded by a sequential, dynamic process via the formation of 
autophagosomes (De Duve and Wattiaux, 1966). Autophagy is further divided into 
various subtypes, which includes chaperone-mediated autophagy, microautophagy 
and macroautophagy (Levine and Klionsky, 2004). Chaperone-mediated autophagy 
is a form of selective autophagy in which long-lived proteins with specific 
pentapeptide motif are being targeted for degradation. Microautophagy involves the 
direct engulfment of the damaged organelles by the vacuolar membrane through 
invagination and/protrusion. In contrast, macroautophagy involves the formation of a 
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double membrane vesicle called the autophagosomes, in which sequestration of long-
lived proteins and organelles take place (Klionsky and Emr, 2000). During 
macroautophagy, dynamic rearrangements of the cytoplasmic membranes occur, and 
though not fully understood; the major molecular events have been uncovered and 
will be discussed in greater lengths in the following sections. In this study, the term 
“macroautophagy” is hereafter referred to as autophagy.  
 
1.4.2 Molecular mechanisms of autophagy 
In response to autophagic signals, including but not limited to nutrient 
starvation, growth factor withdrawal, genotoxic stress and chemotherapeutic drug 
treatments, autophagic process will be initiated. An isolation membrane, also known 
as the phagophore, is formed to enwrap cytoplasmic proteins and organelles to form 
the autophagosomal structures. The autophagosomes undergo a series of maturation 
process before its fusion with the lysosomes to form autolysosomes.  
One of the key players involved in the regulation of autophagy is the Ser/Thr 
kinase mammalian target of rapamycin (mTOR) (Funakoshi et al., 1997; Kamada et 
al., 2000). mTOR is a major negative regulator of autophagy. Under nutrient-rich 
condition, mTOR is responsible for the hyperphosphorylation of Atg13, which would 
then dissociate from Atg1 kinase and Atg13 (Abeliovich et al., 2003; Matsuura et al., 
1997). In contrast, when mTOR is inhibited, Atg13 remains hypophosphorylated, 
allowing its association with Atg1 and Atg17, thereby allowing the formation of a 
multiprotein complex to initiate the autophagic process. 
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 The activity of the Atg13 – Atg1 multiprotein complex drives the vesicle 
nucleation step of the phagophore. A prominent feature in this step involves the 
formation of another multiprotein complex, comprising of Beclin1 (mammalian 
homologue of Atg6), UV irradiation resistance-associated tumour suppressor gene 
(UVRAG), p150 kinase and mammalian VPS34. This multiprotein complex aids in 
the activation of VPS34, a Class III PI3 kinase, resulting in the formation of 
phosphatidylinositol-3-phosphate (PtdIns3P) (Kihara et al., 2001; Nice et al., 2002). 
 During the vesicle elongation steps, a series of conjugation machineries take 
place leading to the formation of autophagosomes. The first conjugation pathway 
involves the conjugation of Atg12 to Atg5, via the intermediacy of Atg10 and the E1-
like enzyme Atg7 (Mizushima et al., 1998; Ohsumi, 2001). This pathway resulted in 
the formation of an Atg12-Atg5-Atg16 homotetramer (Mizushima et al., 1999). The 
second conjugation system starts with the proteolytic activity of Atg4, which cleaves 
the C-terminal region of Atg8, allowing the action of Atg7 for the conjugation of 
Atg8 and Atg3. Finally, a lipid, phosphatidylethanolamine (PE), is being conjugated 
to Atg8 (Ohsumi, 2001). 
 Both Atg12-Atg5-Atg16 complex and Atg8-PE are found at the pre-
autophagsomal structure (PAS), and are believed to play critical role in vesicle 
biogenesis (Kim et al., 2002). Atg12-Atg5- Atg16 complex are found at the 
phagophore, but not at the completed autophagosomes. Atg8-PE, however, are 
localized in both outer and inner membrane of the autophagosomes (Kabeya et al., 
2000). This characteristic enables Atg8-PE to be utilized as a functional marker of 
autophagy. Consistent with this, Atg8 levels increase during starvation-induced 
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autophagy, and its amount are closely correlated with the number of autophagosomes 
(Kirisako et al., 1999). After the execution of autophagy, Atg8 in the outer 
autophagosomes membranes are being recycled to the cytosol, while those in the 
inner membranes are being degraded in the autolysosomes (Kirisako et al., 1999). 
 The whole process of autophagosome formation is elegantly described in 
yeast, the model organism for autophagy. However, the autophagic system in higher 
eukaryotes appears to be highly regulated and similar to its yeast counterparts. In the 
mammalian system, there are a few mammalian homologs of yeast Atg8, including 
gamma-aminobutyric acid receptor-associated protein (GABARAP), golgi-associated 
ATPase enhancer of 16 kDa (Gate-16) and microtubule associated protein 1 light 
chain 3 (MAP1LC3, hereafter referred to as LC3) (Kabeya et al., 2004). Among 
these proteins, LC3 is most extensively studied and its induction is highly correlative 
to autophagic signaling, similar to yeast Atg8. 
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Figure 2: Two conjugation systems involved in autophagosome formation. The 
pathway on the left denotes Atg12-Atg5 conjugation, and on the other side, Atg8-PE 
conjugation pathway. The two pathways are both dependent on Atg7, which is an E1 
ubiquitin-activating enzyme homolog. Both pathways eventually result in the 






1.4.3 Autophagy in health and diseases 
 During normal cellular homeostasis, autophagy occurs at basal level to 
degrade abnormal cellular constituents, thereby contributing to the physiological 
adaptations of eukaryotes. Thus, it is unsurprising that various cellular stimuli, 
including nutrient depletion, hypoxia, high temperature and genotoxic stress 
invariably lead to autophagic induction. In fact, autophagy serves as an important 
cellular adaptation response in normal development and differentiation. In three 
different model organisms, S. cerevisiae, D. discoideum and C. elegans, ATG genes 
are essential in their differentiation process (Melendez et al., 2003; Otto et al., 2003; 
Tsukada and Ohsumi, 1993). During neonatal birth, autophagy is induced after trans-
placental nutrient withdrawal to maintain cellular survival and in this situation, mice 
deficient in Atg5 die one day after delivery (Kuma et al., 2004). By employing GFP-
LC3 staining in various tissues, autophagy is observed in skeletal muscle, liver, heart 
and podocytes in kidney upon nutrient withdrawal of 24 hours (Mizushima et al., 
2004). 
 While normal autophagy is essential for homeostatic maintenance of a 
healthy individual, aberrations in autophagy have also been implicated in various 
disease pathologies.  
 
1.4.4 Autophagy and cell death 
 While basal autophagy constitutes an important survival mechanism towards 
cellular insults, paradoxically autophagic induction has also been associated with cell 
death. Persistent autophagy in response to cellular stress states serves as a potent 
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death signal, as in the case of therapy-induced autophagy, a specific non-apoptotic 
death pathway triggered upon exposure to chemotherapeutic compounds (Amaravadi 
and Thompson, 2007). The latter forms the basis for the identification of type- II cell 
death, characterized by excessive autophagosome formation (Scott et al., 2007; Yu et 
al., 2006).  
It is intriguing that a cytoprotective mechanism in one setting could mediate 
cell killing in other circumstances; hence involvement of autophagy in cell death has 
remained the controversial debates of current literature reviews.  Therefore, it is of 
paramount importance to have proper guidelines for the definition of type-II cell 
death. Type-II cell death, or autophagic cell death is defined as a cell death 
mechanism where macroautophagy represents the only executioner of cell death, 
without any involvement of type-I apoptotic cell death and/ type-III necrotic cell 
death (Scarlatti et al., 2009). A mere observation of autophagic phenotype is not 
sufficient to attribute the cell death as autophagic cell death. In many instances, 
autophagososome formation alone may represent a cellular adaptation response to 
cellular insults, and should not be interpreted as an evidence of cell death (Maiuri et 
al., 2007). In addition, inhibitors of autophagy have also been shown to display 
pleiotropic, non-specific effects (Klionsky et al., 2008). It is thus, imperative; for any 
studies which aim to address a positive role of autophagy in cell death, to 
demonstrate that RNA-mediated silencing of ATG genes confers protection to cell 
death.  
Though type-II cell death is classified as cell death devoid of caspase 
involvement, in many instances autophagy occur simultaneously with apoptosis. A 
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few possible scenarios may arise from this phenomenon. Autophagy may be 
accompanying the cell death but is not involved in the execution of cell death 
(Klionsky et al., 2008). In this instance autophagy may serve as the last desperate 
attempt by the cells to recover cellular viability. In other instances autophagy may 
serve as a signal to trigger the cell death cascade or contribute to the cell death 
response (Hippert et al., 2006). In the latter situation, the cell death could be 
classified as autophagy-dependent cell death. 
In the in vivo setting, there are several examples showing a positive role of 
autophagy in cell death. In a Drosophila melanogaster larval salivary gland system, 
autophagic induction by over-expression of Atg1 was shown to be sufficient to 
induce caspase-independent cell death (Berry and Baehrecke, 2007). Coincidentally, 
in another in vivo model, loss of UNC-51 (C. elegans ortholog of Atg1) suppresses 
necrotic cell death (Samara et al., 2008). These two studies elegantly demonstrate 
that inhibition of crucial autophagy genes rescue cell death, rendering evidence that 
autophagy could indeed be a cell death executioner. Nevertheless, other in vivo 
evidence of autophagy regulation of cell death has been lacking, most likely due to 
limited number of studies involving in vivo models in autophagic cell death. This 
situation is of striking disparity with the pro-survival role of autophagy, which has 
been supported by various in vivo and in vitro studies.  
Despite the scarcity of in vivo studies, there are more evidences in cultured 
mammalian cells which highlight the pro-death role of autophagy. In mouse L929 
fibroblastic cells, gene silencing of Atg7 or Beclin1 reduces the extent of 
nonapoptotic cell death induced by the pan-caspase inhibitor, zVAD (Yu et al., 
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2004). Similarly, caspase inhibition also leads to autophagic cell death due to 
autophagic degradation of catalase and ROS accumulation (Yu et al., 2006). 
Interestingly, several studies support the notion that excessive autophagy invariably 
leads to cell death. Beclin1 mutants, which are defective in binding with Bcl-2, 
induce higher levels of autophagy than wild type Beclin1, and correspondingly, 
increase cell death in MCF-7 cells (Pattingre et al., 2005). Loss of cell viability 
induced by mutant Beclin1 could be effectively rescued by siRNA against Atg5. 
Similarly, direct induction of Atg1 results in high levels of autophagy in D. 
melanogaster. Activation of autophagic pathway then sets the stage for apoptotic cell 
death to occur, which could be blocked by mutant Atg8a (Scott et al., 2007).  
 
1.4.5 Non-canonical autophagy  
The activation of the canonical autophagy pathway is critically under the 
control of the BH-3 only Bcl-2 interacting protein, Beclin1 (Aita et al., 1999). 
Beclin1 was identified as a haplo-insufficient tumor suppressor, monoallelically 
deleted in 40% to 75% of sporadic breast, ovarian and prostate cancers (Boya et al., 
2005). Notably, recent evidence has unraveled a novel autophagic cell death pathway 
wherein Beclin1 is completely dispensible (Yano et al., 2007). This could be of 
paramount importance as the execution of non-canonical autophagy in cancer cells 
bearing a Beclin1 knockout phenotype, could represent a novel and effective strategy 
to induce cancer cell death (Scarlatti et al., 2008). Using a model of neurotoxin-
induced cell death, Zhu et al showed that the existence of autophagic vacuolizations 
was independent of Beclin1 (Zhu et al., 2007). Similarly, in a breast cancer cell 
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model, the phytoalexin resveratrol was found to induce non-canonical autophagy, 
which was dependent on inhibition of mTOR signaling (Scarlatti et al., 2008). 
 
1.4.6 Inducers and regulators of autophagy 
1.4.6.1 Atg proteins 
Advancement in the field of autophagy is greatly accelerated through the 
discovery of a series of autophagy-related (ATG) genes. To date, there are at least 31 
ATG genes in yeast, and their gene products are mainly involved, though not 
exclusively, in the vesicle biogenesis pathway of autophagosome (Yorimitsu and 
Klionsky, 2005). Though the initial studies of the autophagic pathway was explored 
in yeast, the mammalian homologs of the yeast ATG genes has gradually been 
discovered, and this has led to tremendous understanding of the mammalian 
autophagic system (Meijer and Codogno, 2004). Interestingly, the two diverse 
systems have strikingly similar molecular machineries in autophagic regulation, 
suggestive of a highly conserved autophagic adaptation pathway which is essential 
for the well being of an organism. In the mammalian system, most of the ATG genes 
identified, and their products are crucial components of the autophagic system, 
mainly being involved in the regulation of autophagic induction, vesicle nucleation, 
vesicle expansion and the retrieval process (Maiuri et al., 2007). Most of the ATG 
genes which have been extensively studied were discussed in the previous section. 
Among the ATG genes being identified, Beclin1 (mammalian homolog of Atg6) has 
drawn heightened interest as it was identified as a haploinsufficient tumor suppressor 
in a variety of tumor cell lines, being monoallelically deleted in 40-75% of sporadic 
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human breast, ovarian and prostate cancers (Saito et al., 1993; Yue et al., 2003). 
Beclin1 was originally identified as an interacting partner of Bcl-2 in a yeast two-
hybrid screening of adult mouse brain library (Liang et al., 1998). Following its 
discovery, several reports have linked Beclin1 induction to suppression of 
tumorigenesis with a correlating lower level of Beclin1 in activating human tumors 
(Liang et al., 1999; Qu et al., 2003). Interestingly, mammalian Beclin1 belongs to the 
BH3 only protein of the Bcl-2 family members (Oberstein et al., 2007). Apart from 
its canonical role in the vesicle nucleation step of autophagosome formation, Beclin1 
was found to be the interacting partner of Bcl-2 and Bcl-xL, and their interaction has 
intricately linked the Bcl-2 family members to the autophagic pathway (Oberstein et 
al., 2007; Pattingre et al., 2005). 
 
1.4.6.2. PI3-Kinase-Akt-MTOR pathway 
As discussed in the previous section, mTOR is a major negative regulator of 
autophagy. It controls the nucleation step of autophagosome formation. In the 
mammalian system, two classes of PI3-kinase complexes are implicated in 
autophagy. Class I PI3-kinase is an upstream activator of mTOR, and its activation 
which subsequently leads to Akt hyperactivation, has been shown to downregulate 
autophagic response (Coward et al., 2009). Indeed, Akt inhibition has invariably 
linked to a heightened autophagic response (Degtyarev et al., 2009; Degtyarev et al., 
2008). Conversely class III PI3-kinase was shown to be similar to yeast VPS34, it is 
involved in the crucial step of the formation of a multiprotein complex with Beclin1 
and UVRAG. In accordance to this, class III PI3-kinase activity was demonstrated to 
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be important in autophagic induction (Petiot et al., 2000). Thus, it could be deduced 
that a substantial amount of PI3-kinase- Akt pathways on autophagy converged on 
the activity of mTOR. How then, does mTOR display such strong suppression on 
autophagy? Recent report highlighted a direct evidence of mTOR phosphorylation on 
mammalian Atg13 and ULK1 (mammalian homolog of Atg1), thereby inhibiting the 
binding of ULK proteins with FIP200 (Ganley et al., 2009; Jung et al., 2009). 
Importantly, mTOR was found to be incorporated into the ULK1-Atg13-FIP200 
complex in a nutrient-dependent manner, thus highlighting its role as a major 
suppressor during the induction point of autophagy (Hosokawa et al., 2009). 
 
PART II: REACTIVE OXYGEN SPECIES 
Among the several effector mechanisms involved in the control and 
regulation of cell death pathways, including apoptosis and autophagy, is the cellular 
redox status.  The redox status of the cell is determined by the balance between the 
rates of production and breakdown of reactive oxygen and/or nitrogen species (ROS; 
RNS) (Orrenius, 2007), such as superoxide anion (O2
•ˉ), hydrogen peroxide (H2O2), 
hydroxyl radical (OH•), nitric oxide (NO•) and hypochlorus acid (HOCl) (Kamata et 
al., 2005). The term ‘reactive’ is relative, for example O2
•ˉ and H2O2 are more 
selective in their reactions with other biological molecules, while OH˙ is highly 
reactive and reacts quickly with molecules surrounding its vicinity (Halliwell B, 
2007).  
The Free Radical Theory of Oxygen Toxicity states that the deleterious effect 
of oxygen is derived from the conversion of oxygen to partially reduced form of 
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oxygen, such as O2
•ˉ (Fridovich, 1995). Since the inception of this theory in 1954, 
numerous discoveries have been made towards understanding ROS. It is now widely 
recognized that ROS plays a pleiotropic role in mammalian physiology, exerting both 
beneficial and harmful effects to an organism in a context dependent manner. In 
normal circumstances, the generation of ROS is tightly regulated by enzyme 
complexes, such as nitric oxide synthase and NADPH (nicotinamide adenine 
dinucleotide phosphate) oxidase complex (Halliwell B, 2007). ROS production has 
been shown to play critical role in cellular physiology. At physiological 
concentration, ROS mediates cellular defenses against pathogen infections and is 
involved in numerous signaling pathways (Sauer et al., 2001). On the contrary, 
excessive stimulation of ROS production could result in oxidative stress, leading to 
deleterious damage to cells and macromolecules (Buccellato et al., 2004). Damage to 
macromolecules such as proteins, lipids and DNA could result in perturbations of 
their normal cellular functions (Mates and Sanchez-Jimenez, 1999).  Thus, 
overproduction of ROS has been implicated in various disease models. The delicate 
balance between amount of ROS produced and antioxidant defences in organisms 
affects the well being of an organism, and is brought about by various ‘redox-
regulation’ mechanisms in the cells.  
 
2.1 Superoxide anion 
O2
•ˉ is produced by one electron addition to the ground state O2 molecule 
(Halliwell B, 2007). In aqueous solution, O2
•ˉ does not react with most biological 
molecules (Halliwell B, 2007). In aerobic systems, O2
•ˉ can be produced in the cells 
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through many sources. The mitochondrial electron transport chain is suggested to be 
the most important source of O2
•ˉ production, through leakage of electrons from the 
ETC (electron transport chain) component to O2 (Turrens, 2003). Phagocytic cells 
produce O2
•ˉ by utilizing the nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase complex for reduction of O2 during respiratory burst (Halliwell B, 2007). O2 
can also undergo auto-oxidation reactions with biologically important molecules to 
yield O2
•ˉ (Kirsch et al., 2003). Thus, O2
•ˉ has been regarded as one of the primary 
free radical formed from the reduction of O2. Once O2
•ˉ is formed, it could react with 
other molecules to further generate other types of ROS, via various enzyme or metal-
catalyzed reactions (Kamata and Hirata, 1999). O2
•ˉ undergoes dismutation reaction 
to yield H2O2 via the action of superoxide dismutase (SOD) enzyme, and SOD 
represents one of the main antioxidant defense mechanisms in mammalian cells.  
 
2.2 Hydrogen peroxide 
 H2O2 is one of the most important non-radicals in the field of ROS. H2O2 is 
poorly reactive; it does not react with DNA, lipids and most proteins even at high 
concentration (Halliwell B, 2007). H2O2 is only a weak oxidizing or reducing agent. 
It is thus, unsurprising that H2O2 can act as a signaling molecule in the various signal 
transduction pathways. However, H2O2 readily diffuses across cell membranes and 
between organelles (Henzler and Steudle, 2000), and could react with iron and 
copper ions to form the deleterious OH• (Spencer et al., 1995). At low levels, H2O2 
has been reported to have proliferative effects on the cells (Burdon, 1995). When 
being administered at 10 to 100 µM range, H2O2 is toxic to certain cells by activating 
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apoptosis (Burdon, 1995). Higher concentrations would result in necrotic phenotypes 
of the cells.  
 In addition to SOD, H2O2 could also be generated by several different 
enzymes, including xanthine, urate and monoamine oxidases (Halliwell B, 2007).  In 
addition, H2O2 could be generated from oxidation reactions of flavanoids and 
ascorbate (Long et al., 2000). One of the major organelle involved in producing H2O2 
is the mitochondria, by dismutation of O2
•ˉ from the electron transport chain (Boveris 
and Cadenas, 2000). 
Though O2
•ˉ and H2O2 are not particularly reactive, interaction between these 
two molecules yield the highly reactive OH•, which is responsible for the destructive 
effects on biological molecules such as DNA, proteins and lipids. Indeed, OH• is 
responsible for most of the damage incurred in cells treated with H2O2 (Spencer et al., 
1995). In addition, H2O2 could also react with metal ions such as iron or copper to 
generate OH• via Fenton or Haber-weiss reactions (Freeman and Crapo, 1982). 
 
2.3 Intracellular antioxidant defense mechanisms 
 Intracellular concentrations of ROS are determined by the rates of ROS 
production and the rates of ROS elimination by antioxidant defences. Therefore, 
redox regulation represents an important safeguard mechanism to protect living 
organisms from oxidative stress. In vivo, various systems are in place to ensure that 
defense mechanisms are being activated when harmful situation arises for the cells. 
These antioxidant mechanisms are broadly divided into enzymatic and non-
enzymatic antioxidant defences (Halliwell, 1999). Some of the important enzymatic 
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antioxidants include SOD, gluthathione peroxidase (GPx) and catalase. Non-
enzymatic antioxidants in the like of gluthathione, carotenoids, flavonoids, ascorbate, 
α-tocopherol are essential to minimize the adverse effects of ROS on cellular 
physiology.  
 The superoxide theory of oxygen toxicity states that O2
•ˉ is the main 
contributor of oxygen toxicity and thus, highlighting the importance of SOD in 
cellular defenses (Fridovich, 1995). SOD efficiently catalyses the removal of O2
•ˉ in 
the cells, by accelerating the dismutation of O2
•ˉ to H2O2. Copper- and zinc- 
containing superoxide dismutase (CuZn SOD) are mainly found in the cytosol of 
animal cells, while manganese SOD (MnSOD) are almost entirely located in the 
mitochondria (Okado-Matsumoto and Fridovich, 2001).  
 Dismutation of O2
•ˉ results in the formation of H2O2. H2O2 can be effectively 
converted into molecular oxygen and water through the enzymatic activity of catalase 
(Lardinois, 1995). All animal organs contain catalases, with the highest amount 
found in the liver (Lardinois, 1995). In animal cells, catalases are mainly found in the 
peroxisomes, which are also the sites of H2O2 production (Halliwell B, 2007).  
 Glutathione (GSH) is ubiquitously found in animals, plants and aerobic 
bacteria. It is also present in various cellular compartments including cytosol, nucleus 
and mitochondria and serves important antioxidant functions in these compartments. 
GSH is reduced to GSSG by the action of GPx, thereby facilitating the conversion of 
H2O2 to water (Kosower and Kosower, 1978). In addition, GSH could also directly 
scavenge OH• and singlet oxygen (Halliwell B, 2007). 
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2.4 Reactive Oxygen Species and Cell Death  
 ROS has been widely regarded as an effector mechanism of cell death. 
Numerous studies have provided evidence that inducers of apoptotic cell death also 
turn out as generators of ROS (Haddad, 2004). Correspondingly, amelioration of 
ROS generation by antioxidants attenuates the cell death progression. In most 
experimental systems, ROS production does not directly lead to cell death. In turn, 
ROS serves as important signaling molecule in the activation of the apoptotic 
signaling cascade (Mates and Sanchez-Jimenez, 2000). In the in vitro models, 
exogenous addition of oxidants culminates in the accumulation of oxidative stress 
leading to cell death. Exposure to high level of oxidative stress results in cellular 
injury in the form of macromolecular damage. In addition, cellular antioxidant 
defenses are depleted following excessive oxidative insults, thereby lowering 
threshold for apoptosis to occur (Kong et al., 2000). 
 Ionizing and UV irradiation trigger apoptosis through induction of H2O2 and 
OH• production. Cellular response to H2O2 is largely dependent on the concentration 
of oxidant. Low to medium H2O2 concentration frequently results in apoptosis, while 
excessive amount of H2O2 exposure invariably leads to necrotic cell death. It has 
been reported that H2O2-induced cell death is dependent on mitochondrial 
permeabilization and cytochrome c release, eventually resulting in caspase activation 
(Haddad, 2004; Kannan and Jain, 2000). Exogenous addition of H2O2 or drug-
induced H2O2 production in cancer cells is frequently accompanied by a drop in pHi, 
thereby creating a permissive intracellular milleu for apoptotic cell death (Pervaiz 
and Clement, 2002b). Another mechanism which has been proposed for H2O2-
 28
mediated cell death involves the activation of apoptosis signal-regulating kinase 1 
(ASK1), which could undergo dimerization upon H2O2 treatment to the cells (Gotoh 
and Cooper, 1998). 
Numerous findings have demonstrated a direct association between ROS and 
the death receptor signaling pathways. Exogenous addition of ROS or the utilization 
of ROS-generating compounds have been shown to upregulate CD95 and TRAIL 
death receptors. Arsenic trioxide, which could induce intracellular ROS production, 
activates nuclear factor of kappa light polypeptide gene enhancer in B-cells (NFκB) 
transcription factor which in turn facilitates the transcription of CD95 (Woo et al., 
2004). In addition, ROS could signal for CD95 clustering at the cell membrane, 
which is inhibited by antioxidants treatment (Huang et al., 2003). Fas- stimulated 
ROS production is critical in apoptosome formation in Jurkat T cells, subsequently 
promoting caspase-9 and caspase-3 activation (Sato et al., 2004). Uncoupling of 
oxidative phosphorylation by using carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) results in mitochondrial ROS formation, thereby sensitizing human colon 
carcinoma cells to TRAIL-induced release of Smac/DIABLO and caspase-3 
activation (Izeradjene et al., 2005). 
As discussed previously, mitochondria is the major site of ROS production in 
the cell (Jezek and Hlavata, 2005). Thus, it is logical to deduce that ROS generated 
within mitochondria could represent an important regulatory axis in mitochondrial-
dependent cell death. Indeed, ROS generation could target the mitochondrial 
membrane permeabilization, thereby facilitating cytochrome c release and 
downstream cell death effectors activation. In addition, H2O2 has been shown to be 
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an important signaling molecule in triggering Bax translocation to the mitochondria, 
through enhancing cytosolic acidification of tumor cells (Ahmad et al., 2004b). 
Interestingly, H2O2-mediated Bax translocation results in increased H2O2 amount in 
the mitochondria, further amplifying the death signals. Acidification of the 
intracellular milleu provides a more conducive environment for efficient caspase 
activation (Hirpara et al., 2001). H2O2- induced apoptosis is ablated by 
overexpression of Bcl-2 in tumor cells (Clement et al., 2003). In correlation with the 
abovementioned studies, protective role of Bcl-2 in intracellular acidification-
mediated cell death is due to a slight elevation of O2
•ˉ and intracellular pH (Pervaiz 
and Clement, 2002b). Conversely, by means of decreasing the intracellular 
concentration of O2
•ˉ, Bcl-2- overexpressing cells are being sensitized to drug- 
induced apoptosis (Clement et al., 2003). These observations lend credence to a 
regulatory role of O2
•ˉ and H2O2 in determining sensitivity of tumor cells to drug-
induced apoptosis. 
   
PART III: MAPK SIGNALING PATHWAYS 
   Cellular response to environmental changes requires an intricate balance of a 
wide range of intracellular signaling networks. Cells have the ability to adapt to 
extracellular and intracellular alterations such as growth factors, cytokines, ligand 
binding, cellular matrix adhesion and nutritional cues (Davis, 2000). Cells also need 
to respond to physical fluctuations in temperature, pH and environmental stresses. 
Intracellular signaling pathways are interconnected and act in a cooperative manner 
to mount an appropriate response towards physiological demands of the cells. It is 
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thus not surprising that the integrated signaling networks control and regulate cellular 
physiology in terms of cell proliferation, differentiation and cell death. 
  Of the major intracellular signaling pathways, mitogen activated protein 
kinases (MAPK) is shown to be important in mitigating cellular responses. To this 
end, MAPK have been identified to be evolutionarily conserved among eukaryotes. 
Evolutionarily, MAPK are organized into three-tier kinase signaling module, 
comprising of Mitogen activated protein kinase kinase kinase (MAPKKK), Mitogen 
activated protein kinase kinase (MAPKK) and MAPK (Johnson and Lapadat, 2002). 
Signal transduction which relays through the MAPK signaling module eventually 
leads to the translocation of MAPK into the nucleus and activate transcription factor. 
Thus, MAPK activation plays an integral role in the regulation of gene expression. 
Activation of the MAPK cascade is achieved through sequential phosphorylation of 
the MAPK signaling components (Wada and Penninger, 2004).  
  Genetic studies in the yeast Saccharomyces cerevisiae have led to the 
identification of five MAPK modules which are involved in mating, osmoregulation, 
sporulation, cell wall remodeling and filamentation (Schaeffer and Weber, 1999). In 
mammals, three MAPK modules have been identified, and are named after the last 
kinase in the series. Each MAPK is activated by dual phosphorylation of a tripeptide 
motif, Thr-Xaa-Tyr (Johnson and Lapadat, 2002). Though each MAPK carries out 
unique biological functions, there is overlapping of the components of the three 





              
 
Figure 3: MAP kinase signaling modules. The MAPK are activated via dual 
phosphorylation of Thr and Tyr residues by MAPKK, which are in turn 
phosphorylated by MAPKKK. This linear diagram is a simplified representation of 
the signaling modules, and it should be noted that the complexities and cross-talk 
often exists between the various modules depending on the specific cellular context. 








3.1 The ERK signaling cascade 
 ERK is encoded by 2 different genes, ERK1 and ERK2, which give rise to 
two main proteins, p44 and p42 (Boulton et al., 1991). It was previously described 
that ERK1 and ERK2 shares 84% homology and have overlapping functions (Lloyd, 
2006).  
 As a critical MAPK involved in the integration of cellular signaling network, 
it is unsurprising that ERK has been documented to play a diverse role in various 
cellular and physiological processes. ERK was shown to be functionally important in 
cell cycle control, differentiation, migration, proliferation, survival signaling, cellular 
senescense and migration (Rubinfeld and Seger, 2005). Given that ERK could 
mediate numerous physiological functions, it is unsurprising that ERK is implicated 
in multiple disease pathologies, such as cancer, diabetes and cardiovascular diseases.  
 ERK could be activated in response to a diverse range of extracellular factors, 
which includes growth factors, cytokines and neurotransmitters (Chang et al., 2003). 
These signals are transmitted via cell surface receptors, such as G- protein coupled 
receptors (GPCR), integrin receptors and tyrosine kinase receptors before being 
relayed through the ERK signaling cascade (Ramos, 2008). In a typical ERK 
signaling cascade, binding of extracellular ligands to the cell surface receptors would 
result in the receptor activation, followed by recruitment of adaptor proteins, such as 
Grb2, which would then bind to the Guanine exchange factors (GEF) of small GTP 
binding proteins. Activated GEF would in turn lead to activation of the small 
GTPases, such as Ras (Omerovic et al., 2007). Stimulation of Ras initiates the 
sequential activation of ERK signaling cascade, by transmitting the signals to 
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MAPKKK. MAPKKK, such as Raf-1, is then being recruited to the plasma 
membrane and mediates the activation of MEKs, including MEK1 and MEK2 
(Fukuda et al., 1997). Activation of MEKs is mediated by phosphorylation at their 
signature Ser-Xaa-Ala-Xaa-Ser/Thr motif in the activation loop (Ramos, 2008). 
MEK activation represents a critical regulatory domain of ERK signaling as MEK1 
and MEK2 display exceptionally high specificity towards native form of ERK (Seger 
et al., 1992). Another high degree of specificity lies in the fact that phosphorylation 
by MEK is the only upstream mechanism in vivo which can lead to ERK 
phosphorylation (Rubinfeld and Seger, 2005). MEKs are dual specificity protein 
kinases, being able to phosphorylate ERK at Thr and Tyr residues of the Thr-Glu-Tyr 
motif at their activation loop (McKay and Morrison, 2007). Once activated, ERK 
could undergo dimerization as well as translocation to the nucleus. Apart from 
activation of transcription factors residing in the nucleus, a multitude of intracellular 
targets have also been identified as ERK’s substrates. 
 
3.2 Substrates of ERK 
 ERK is known as ‘proline-directed’ kinase, for its ability to phosphorylate 
Ser/Thr residues that are followed by Pro. In general, ERK recognises the consensus 
sequence Pro-Leu-Ser/Thr-Pro, though other sequences have also been identified 
previously (Gonzalez et al., 1991). Therefore, ERK have been shown to have a broad 
range of substrates pool. 
 One group of the best studied substrates of ERK is the nuclear transcription 
factors. The ternary complex factors (TCFs), is a class of transcription factors with 
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members such as Elk-1, SAP-1 and SAP-2, which are known ERK substrates 
(Pearson et al., 2001). ERK-mediated phosphorylation of Elk-1 occurs on the C-
terminus transactivating domain of Elk-1, and is able to potentiate the formation of 
ternary complexes (Gille et al., 1995).  
 In addition, another important class of transcription factors, namely activator 
protein-1 (AP-1) family of transcription factors were also identified to be ERK’s 
targets. Among which, c-Jun, c-Fos and ATF-2 have all been shown to be 
phosphorylated by ERK (Morton et al., 2003; Murphy et al., 2002). Notably, 
phosphorylation of c-Jun by ERK occurs at the C-terminus inhibitory sites, 
preventing c-Jun from binding to the DNA, as opposed to transactivating domain in 
the case of JNK. This seems to suggest an opposing function for these Map kinases, 
at least in terms of regulation of c-Jun.  
 Apart from nuclear proteins, many cytosolic proteins have been identified as 
ERK targets. The kinases ribosomal S6 kinase (RSK), mitogen and stress-activated 
protein kinase (MSK) and Map kinase interacting kinase (MNK) are downsteam 
substrates of ERK and may serve to relay the propagating signals to mediate a wide 
array of cellular responses (Roux and Blenis, 2004). In addition, ERK also mediate 
the phosphorylation of cytoskeletal proteins, such as synapsin 1, vinexin and paxillin 
(Jovanovic et al., 1996; Ku and Meier, 2000; Mitsushima et al., 2004). Importantly, 
the evidences of ERK in mediating phosphorylation of its upstream activators such as 
Raf, MEKs and the guanine nucleotide exchange factor, son of sevenless (SOS) 
suggest that feedback inhibition is a regulatory mechanism in ERK signaling 
pathway (Dougherty et al., 2005; Eblen et al., 2004; Langlois et al., 1995).  
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3.3 ERK and oncogenesis 
 Activation of the canonical MEK-ERK pathway has been classically linked to 
proliferation and oncogenic transformation. Several lines of evidence are in support 
of this. Activation of the ERK cascade has been associated with tumor promotion, in 
both in vitro and in vivo models (Kyriakis et al., 1992; Sobczak et al., 2008). 
Conversely, inhibition of the ERK pathway could effectively contain tumorigenic 
progression (Murphy et al., 2006; Ouyang et al., 2006). MEK1, which directly 
activates ERK, has also been implicated in malignant transformation. The findings on 
the effect of constitutive activation of MEK1 in the induction of oncogenesis, 
coupled with dominant negative form of MEK1 which reversed tumor formation, 
have indicated a direct role of ERK in the regulation of neoplasia (Cowley et al., 
1994; Manser et al., 1994; Seger et al., 1994). More importantly, ERK activation is 
often induced by mitogenic signals, and could lead to transcription factor activation. 
Thus, ERK signaling has been shown to integrate mitogenic signals to induce 
oncogenic transformation. For instance, activation of Elk-1 by ERK could lead to 
induction of c-fos, which is a transcription factor predominantly associated with cell 
growth and cell cycle progression (Marais et al., 1993; Whitmarsh et al., 1995).  
  
3.4 Erk and cell death 
 While it is true that the current literature has attributed a pro- growth and 
proliferation role to ERK activation, it is not queer that in certain cellular systems, 
ERK has also been demonstrated to participate in cell death. It should be an 
important note, however, that the association between ERK and induction of 
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apoptosis is by no means as established as its role in proliferation and oncogenic 
transformation. There are many correlative evidences between ERK and cell death, 
but the molecular mechanisms detailing the interactions between the two remained 
poorly understood.  
 Regardless of the ambiguity in relation to dual roles of ERK in survival and 
death, it is at least certain that DNA damage-induced ERK activation invariably 
culminates in a cell death response. Various DNA damaging agents, such as 
etoposide, cisplastin and UV irradiation could stimulate ERK activity, and altering 
the state of ERK activation ultimately lead to a reduction or complete cessation of the 
apoptotic response, placing ERK as a central feature of DNA damage-induced cell 
death (Lee et al., 2000; Tang et al., 2002; Wang et al., 2000). 
 Interestingly, ROS production has been shown to be a critical event leading to 
DNA damage. Along the same line, the ability of various DNA damaging drugs in 
triggering apoptosis has been attributed to an overwhelming production of ROS (Kim 
et al., 2005b). In view of the fact that ERK inhibition could abrogate ROS-mediated 
cell death in many circumstances, it is not impossible that the DNA damage-induced 
signaling pathway is dependent on ERK status in certain cases (Dong et al., 2004; 
Wang et al., 2000).  
 Apart from DNA damaging agents, Fas was also shown to be an activator of 
ERK and expectedly, abrogation of ERK also attenuated Fas-mediated cell death 
signaling (Goillot et al., 1997; Holmstrom et al., 2000). Nevertheless, as mentioned 
previously, progress in cell death research involving ERK have been lagging due to 
the lack of molecular evidences supporting ERK’s involvement in cell death. 
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3.5 ERK and autophagy 
 Though the involvement of ERK in autophagy is not as established as other 
major regulators of autophagy, such as JNK and Bcl-2, there are several lines of 
evidence indicating a relationship between ERK and autophagy.  
 Most of the current literatures have pointed to a positive regulatory role for 
ERK in regulating autophagy. The positive association linking ERK and autophagy 
have been demonstrated in studies involving TNF-α-induced autophagy (Cheng et 
al., 2008; Sivaprasad and Basu, 2008), as well as in neurotoxin-induced autophagic 
cell death (Zhu et al., 2007). These studies demonstrated a role for ERK in 
autophagic-mediated cell death. Similarly, ERK was implicated in starvation-induced 
autophagy leading to a cytoprotective response (Ogier-Denis et al., 2000). It is 
noteworthy that while consequences of ERK-elicited autophagy vary among different 
model systems, all of the studies mentioned above demonstrated an unequivocal role 
of ERK in autophagy by showing that pharmacological inhibition of ERK was found 
to be sufficient to impede autophagic progression.  
 At the molecular level, several mechanisms have been delineated with regards 
to ERK-mediated autophagy. One of the mechanisms involves phosphorylation and 
activation of Gα-interacting protein by ERK, which could then kick start the 
initiation process of autophagy (Ogier-Denis et al., 2000). Another recent publication 
has described a unique, dual role of ERK in mediating autophagy (Wang et al., 
2009). The findings in this paper showed that moderate activation of ERK can lead to 
a moderately high level of Beclin1, which results in protective autophagy. On the 
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other hand, sustained activation of ERK causes high level of Beclin1 which is 
responsible for destructive autophagy (Wang et al., 2009). 
 
3.6 The JNK/SAPK signaling cascade 
  The c-Jun NH2-terminal kinase (JNK), otherwise known as the stress-
activated protein kinase (SAPK) is activated by dual phosphorylation at specific Thr-
Pro-Tyr residues (Davis, 2000). JNK is commonly stimulated by various cytokines 
and environmental stressors, including UV radiation, oxidative stress and osmotic 
stress (Weston and Davis, 2002; Weston et al., 2002). JNK was initially identified as 
a “p54- microtubule associated protein” which was activated following 
cyclohexamide treatment (Kyriakis and Avruch, 1990). Soon after, JNK was found to 
be a specific kinase responsible for the transcription factor, c-Jun activation by 
binding to the N-terminus activation domain of c-Jun (Hibi et al., 1993). The ability 
of JNK to activate c-Jun is due to the kinase activity of the protein, being able to 
phosphorylate c-Jun on Ser-63 and Ser-73 residues (Pulverer et al., 1991).  
  c-Jun belongs to the activator protein-1 (AP-1) transcription factor family. 
Phosphorylation of c-Jun by JNK on the N-terminus transactivation domain results in 
induction of c-Jun expression (Ip and Davis, 1998; Smeal et al., 1991). Apart from 
activating c-Jun, JNK also phosphorylates other AP-1 proteins, including JunB, JunD 
and activating transcription factor 2 (ATF-2) (Ip and Davis, 1998). Most of the 
cellular effects brought about by JNK have been attributed to its ability to 
transcriptionally activate AP-1. 
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  JNK proteins are encoded by three different genes, Jnk1, Jnk2 and Jnk3. Jnk1 
and Jnk2 are ubiquitously expressed, while Jnk3 expression is tissue specific, mainly 
being restricted to the brain, heart and testis (Kyriakis et al., 1994; Weston et al., 
2002; Yang et al., 1997). Alternative splicing of these three genes results in ten 
isoforms of JNK (Gupta et al., 1996). JNK proteins are expressed as the short form 
(46 kDa) and long form (54 kDa) isoforms, with the latter having a COOH terminal 
extension (Pulverer et al., 1991). The different isoforms of Jnk genes appear to 
encode for different splice variants which differ in their substrate recognition and 
activation profile. 
 JNK mediates diverse roles in response to cellular stress. The exact biological 
outcome derived from JNK activation is often stimulus-specific and context-specific. 
Nevertheless, JNK has been implicated in various cellular processes such as 
apoptosis, autophagy, diabetes, metabolism and lifespan (Weston and Davis, 2007). 
In line with the scope of this study, the role of JNK in autophagy, cell death and 
tumorigenesis will be discussed in the following sections. 
 
3.7 JNK and apoptotic cell death 
 Numerous experimental evidences have suggested that JNK can function as a 
pro-apoptotic kinase. Firstly, association studies with either dominant negative or 
gain-of-function components of the JNK pathway confirmed the contribution of JNK 
in promoting apoptosis (Xia et al., 1995; Yang et al., 1997). In addition, genetic 
studies involving Jnk1, Jnk2 or Jnk3 genes have established a stimulatory role for 
JNK in neuronal apoptosis (Kuan et al., 2003; Tournier et al., 2000).  
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 One of the main discoveries with regard to JNK and apoptosis involved the 
interplay between JNK and NFκB pathway. TNF-α is a pro-inflammatory cytokine 
which could induce apoptosis or survival in a context dependent manner. It is 
generally suggested that TNF-α only induce apoptosis when NFκB activation is 
inhibited (De Smaele et al., 2001; Kamata et al., 2005; Sakon et al., 2003). The state 
of NFκB activation determines the temporal activation of JNK (Cavigelli et al., 1996; 
Liu et al., 1996). When the components of NFκB activation is deficient, in the case 
of IKK or Rel A deletion, JNK could be activated in a prolonged and sustained 
manner, thereby promoting apoptosis (Maeda and Karin, 2003). Though these studies 
demonstrated an integral role of JNK and NFκB in determining cell fate in TNF- α- 
induced apoptosis, the crucial players involved in this interplay are still at large. 
Several candidates have been suggested to mediate NFκB- induced JNK inhibition, 
including X-linked inhibitor of apoptosis protein (XIAP), growth arrest and DNA 
damage 45 (GADD45) and the MAPKK, MKK7 (De Smaele et al., 2001; Tang et al., 
2001). 
 One way to determine the role of JNK in apoptosis was to investigate the 
interactions between JNK and the components of the apoptotic pathway. Thus, 
numerous studies were carried out to determine potential targets of JNK in the 
apoptotic signaling. Fas-L was shown to be one of the downstream targets of JNK 
and following its induction, apoptotic death signaling was enhanced (Faris et al., 
1998; Kasibhatla et al., 1998; Lin et al., 1998). On a separate note, JNK has also been 
shown to phosphorylate murine p53 on Ser-34 residues in an in vitro model (Milne et 
al., 1995). In addition, human p53 was also identified as a JNK substrate (Fuchs et 
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al., 1998a; Fuchs et al., 1998b). In stress-induced apoptosis, p53 phosphorylation by 
JNK led to inhibition of p53 degradation, leading to p53 stabilization (Fuchs et al., 
1998b). In another setting, interaction of JNK and c-Myc was found to contribute to 
apoptosis (Noguchi et al., 1999). JNK was previously shown to phosphorylate c-Myc 
on Ser-62 and Thr-71 residues (Noguchi et al., 1999). The involvement of JNK in c-
Myc- induced apoptosis was further strengthened by dominant negative experiments 
of JNK.  
 In the exploration of mechanisms involved in JNK-mediated apoptosis, 
experimental evidences seemed to point to the mitochondria as a critical point of 
regulation. Jnk null MEFs were unable to induce MOMP or cytochrome c release, 
suggesting that JNK may be an intrinsic component of the mitochondrial death 
pathway (Tournier et al., 2000). Indeed, JNK activation has been linked to effective 
cytochrome c release from the mitochondria (Hatai et al., 2000). This phenomenon 
might be linked to c-Jun activation, as mutations of JNK phosphorylation sites on c-
Jun partially impaired UV-induced apoptosis (Behrens et al., 1999). Another possible 
mechanism for JNK-induced cytochrome c release involved the action of JNK on the 
Bcl-2 family members. It was proposed that JNK was responsible for the 
phosphorylation of Bcl-2 and Bcl-xL in both in vitro and in vivo systems, and this 
was postulated to be inhibitory to their function as anti-apoptotic regulators 
(Maundrell et al., 1997; Yamamoto et al., 1999). Along similar lines, JNK’s 
contribution in mitochondrial death pathway could be linked to the production of 
jBid, which is a novel cleaved fragment of Bid (Deng et al., 2003). jBid was 
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produced following prolonged activation of JNK, and was found to be effective in 
the release of mitochondrial SMAC, thereby activating the intrinsic death pathway.  
 Targeted disruption of Jnk genes represents a useful approach in detecting 
alterations in apoptotic components. Research involving Jnk1-/-Jnk2-/- mouse 
embryonic fibroblasts (MEFs) provided a powerful model in the investigations of 
JNK-induced apoptosis (Tournier et al., 2000). Jnk null MEFs were fully capable in 
the execution of Fas-induced cell death, indicating a dispensable role of JNK in death 
receptor-mediated apoptosis in MEFs. In contrast, Jnk null MEFs failed to promote 
stress-induced apoptosis and these cells could not execute efficient caspase 
activation. These studies provide useful insights on the apoptotic response mediated 
by JNK signaling circuitry.  
 
3.8 JNK and autophagy 
 In addition to the many complexities in JNK-regulated pathways, many 
reports have associated an increase in JNK activity to autophagic regulation. JNK 
was first shown to be critical for zVAD-induced cell death in L929 cells, and JNK 
inhibition suppressed the extent of autophagosome formation and cell death (Yu et 
al., 2004). In addition, neurotoxin-induced autophagic death was associated with 
JNK and c-Jun activation (Borsello et al., 2003). In a different setting, JNK activity 
was found to be essential in ER stress-induced autophagy (Ogata et al., 2006). 
However, in this model, induction of JNK-dependent autophagy was shown to be 
important for cell survival.  
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 While the earlier studies have unravelled a role for JNK kinase in the 
regulation of autophagy, the molecular mechanisms involving JNK was 
undetermined in these studies. Most of the studies presented an association of JNK 
and autophagy through the utilization of specific inhibition of JNK kinase activity via 
pharmacological inhibitors, such as SP600125 and U0126, or gene silencing 
technology targeted against JNK 1/2.  
 Recent data has pointed to Beclin1-Bcl2 complex as a putative JNK target. 
Under non-starvation condition, Beclin1 was found to be able to bind to Bcl-2, and 
their interaction was shown to be an important inhibitory function of Bcl-2 to keep 
the autophagic response in check (Pattingre et al., 2005). One of the earliest 
mechanisms of JNK identified in the modulation of autophagy was associated with 
its extra-nuclear function. Specifically, JNK1 was identified to be the kinase 
responsible for Bcl-2 phosphorylation, resulting in the disruption of Beclin1-Bcl-2 
complex, thereby promoting starvation-induced autophagy (Wei et al., 2008a). Apart 
from the inactivation of protein complex from outside of the nucleus, transcriptional 
activity of the JNK signaling pathway was found to be crucial in increasing Beclin1 
expression in the activation of autophagic cell death (Li et al., 2009; Park et al., 
2009).  
 Despite the numerous studies linking JNK and autophagy, the mechanism of 
action involved in JNK signalling with regard to autophagy has been limited to Bcl-2 
and Beclin1 regulation. Efforts to decipher the specific stimulus and context within 
which JNK activation was induced and the eventual purpose of JNK-mediated 
autophagic signaling remained an interesting biological function to be explored. 
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3.9 JNK and cell survival 
 Conventionally, JNK has been regarded as a pro-apoptotic kinase, supported 
by the bulk amount of data in the literature showcasing its pro-death activity. The 
literature provided in the previous section is definitely not an exhaustive list which 
demonstrated an association of JNK and cell death. In spite of the acceptance of JNK 
as a death-promoting protein, it is unsurprising that on the other hand, evidence 
supporting a pro-survival role of JNK has also been demonstrated. Consistent with 
this, many extracellular stimuli which activate JNK could also directly result in cell 
survival. For instance, TNF-α-induced JNK activation in fibroblasts was linked to 
cell survival and completely independent of the cell death pathway (Liu et al., 1996). 
JNK activation has also been demonstrated to be crucial for integrin- mediated 
cellular survival (Almeida et al., 2000). In addition, another convincing evidence 
linking JNK to anti-apoptosis came from the studies on Jnk deletion mutants. Jnk1 
and Jnk2 null mice were prone to apoptosis in the forebrain and hindbrain regions, 
indicating that JNK could be involved in mitigating the survival response in these 
brain regions during development (Kuan et al., 1999; Sabapathy et al., 1999). In view 
of the pleiotropic roles of JNK in cell signaling, it should be borne in mind that the 







3.10 JNK and tumorigenesis 
 The activity of JNK is intricately linked to cell death and cell survival. Thus, 
studies which implicate JNK in carcinogenesis are also mainly based on these two 
cellular responses.  
 An important line of evidence in JNK-mediated oncogenic transformation 
comes from JNK’s ability to phosphorylate the transcription factor c-Jun. Oncogenic 
transformation induced by Ras requires c-Jun and this phenomenon could be 
effectively ablated via c-Jun mutation on sites that are phosphorylated by JNK 
(Nateri et al., 2005). In addition to this, JNK have been implicated in various studies 
which employed tumor promoters and chemical carcinogens (Chen et al., 2001; 
Sakurai et al., 2006). These studies have proposed that JNK represents an ideal anti-
tumor target as suppression of JNK activity could restrict tumor growth and 
proliferation. 
 In contrast, several other studies have established a tumor suppressor role for 
JNK. The rationale in search of a tumor suppressor gene in the JNK pathway lies in 
the argument that if JNK was implicated in apoptosis, then at least one of the 
components of the JNK pathway should be a putative tumor suppressor. The most 
realistic candidates would be the Jnk1 or Jnk2 genes; however, as these genes are 
largely functionally redundant, it is highly unlikely that they could act as tumor 
suppressors. In this regard, MKK4, which acts upstream of both JNK and p38 in the 
MAPK signaling module, was identified as a candidate tumor suppressor gene (Su et 
al., 1998; Teng et al., 1997). Loss of function mutations of MKK4 have been 
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identified in various cancers (Su et al., 1998; Su et al., 2002). In addition, epigenetic 
loss of MKK4 has also been associated with increased metastasis of ovarian and 
prostate carcinomas (Xin et al., 2004; Yamada et al., 2002). However, it should be 
clear that though MKK4 represents an ideal anti-tumor target, its effect should not be 




















MATERIALS & METHODS 
 
In this study, the properties of C1 as an anti-tumor compound were being evaluated. 
In particular, the cellular response triggered by C1 was assessed. Various methods of 
detecting autophagy and apoptosis, as well as general cell proliferation were 
employed to determine the cellular processes involved in C1-treated cells. In 
addition, examinations of the cellular signaling pathways were carried out with 
inhibitors and RNAi-mediated silencing of the Map kinase family members, ERK 
and JNK. These experimental methods are summarized as below:  
 
1 Synthesis and analysis of the small molecule compound C1: 
The small molecule compound 1, 3-dibutyl-2-thiooxo-imidazolidine-4, 5-dione, 
herein referred to as C1, was synthesized as follows: Oxalyl chloride was added to 1, 
3-dibutyl-2-thiourea (10 mM) in anhydrous ether in a round bottom flask under 
stirring. The reaction mixture was stirred for 1 to 2 hours at ambient temperature and 
then poured into saturated NaHCO3. The product was extracted with 3X ethyl 
acetate. The ethyl acetate layer was then washed with distilled water and then brine 
water. Ethyl acetate was then dried with anhydrous Mg2SO4 and removed under 
reduced pressure. The purification through flash chromatography (ethyl 
acetate:hexane) afforded the yellow oil product. The oily product was solidified in a 
refrigerator. The compound was then analyzed by HNMR, C NMR and MS and 
results are presented as follows: Name: 1,3-dibutyl-2-thiooxo-imidazolidine-4,5-
dione; Color: Orange; FT-IR (in CH2Cl2):  2875-2960 cm
-
 (Aliphatic CH), 1770 
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(C=O), 1410 (C=S); 
1
HNMR (in CDCL3): δ = 0.95 9 (t, J=7.3Hz, 6H, 4’-CH3), 1.34 
(sext, J=7.7 Hz, 4H, 3’-CH2), 1.67 (quint, J=7.2 Hz, 4H, 2-CH2) 3.93 (t, J=7.5 Hz, 
4H, 1’-CH2); C NMR (in CHCl3): δ = 13.54 (C4’), 19.90 (C-3’), 29.72 (C-2’), 41.83 
(C-1’), 155.35 (C-4.5), 180.63 (C-2); Mass m/z (%): 242 (100) [M+], 209 (26) [M+ -
HS], 187(22); MF C11H18N2O2S calculated 242.34, Found 243.34. 
Yield:  95% 
 
2 Tumor cell lines: 
HCT116 colorectal carcinoma cells were generously provided by Dr. Bert Vogelstein 
(The Johns Hopkins University School of Medicine, Baltimore, MD) and maintained 
in McCoy 5A (Gibco Invitrogen Corporation, Carlsbad, CA) supplemented with 10% 
fetal bovine serum FBS), 1% L-glutamine, and 1% S-Penicillin (Hyclone, Thermo 
Scientific, Waltham, MA) in a 37°C incubator with 5% CO2. HeLa cervical 
carcinoma, A549 small cell lung carcinoma, M14 melanoma, SHEP1 and SHSY5Y 
neuroblastoma cell lines were obtained from ATCC and maintained in DMEM 
(Hyclone) supplemented with 10% FBS. MCF-7, T47D, and MDA-MB-231 breast 
cancer cell lines were from American Type Culture Collection (ATCC) and cultured 
in RPMI (Hyclone) supplemented with 10% FBS. HK-1, C666-1 nasopharyngeal 
carcinoma cell lines, gifted by Dr. Lo Kwok-wai (The Chinese University of Hong 
Kong) and Dr. Hsieh Wen-son (Johns Hopkins Singapore), were maintained in RPMI 





3 Reagents and chemicals: 
The pan-caspase inhibitor, ZVAD-FMK, and the caspase 3 and 9 inhibitors (DEVD-
fmk and VEHD-fmk) were obtained from Alexis Biochemicals, Lausen, Switzerland. 
The JNK inhibitor (SP600125), the ERK inhibitor (PD98059), bovine catalase, N-
acetyl-cysteine, MG132, cyclohexamide, actinomycin D, crystal violet, and MTT 
were purchased from Sigma Aldrich, St. Louis, MO. 
 
4 Plasmids and siRNAs: 
The plasmid pGFP-rLC3 was a generous gift from Professor T. Yoshimori (National 
Institute of Genetics, Shizuoka, Japan). siRNAs for Beclin1, Atg7, JNK1/2, ERK1/2 
and ULK-1 were obtained from Dharmacon Technologies (Thermo Scientific, MA).  
The pCINeoEV empty vector and pCINeo+Cat containing the full-length human 
catalase gene were a gift from Dr. Marie-Veronique Clément (Department of 
Biochemistry, National University of Singapore). 
 
5 Amplification and purification of plasmids 
Amplification of plasmids was carried out by using NucleobondTM DNA purification 
kit according to the manufacturer’s manual. Briefly, 100 µl of Escherichia coli 
(E.coli) competent cells were incubated with 100 ng of each plasmid at 4 °C for 3 
min before being subjected to heat-shock treatment for 1 min at 37 °C, then being 
incubated at 4 °C again for 5 mins. The cells were then added to 900 µl of super 
optimal catabolite repression (SOC) buffer and the mixture were incubated at 200 
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rpm for 30 mins in a 37 °C bacterial incubator with 5% CO2. Next, 100 µl of the 
mixture were plated on lysogeny broth (LB) plates which was prepared with 
Ampicillin antibiotics, then being incubated at 37 °C for 16 hours. A mini culture 
was made by selecting a single cell colony from the agar plate and incubating it with 
4 ml of LB medium containing ampicilin antibiotic for 16 hours at 37 °C. Following 
which, the mini culture was transferred to a maxi culture by adding 1 ml of mini 
culture to 250 ml of LB medium containing ampicilin antibiotic and the mixture 
broth was incubated for 16 hours at 37 °C. Next the maxi culture was being 
centrifuged at 2500 rpm for 30 min at 4 °C. The E. coli pellet was resuspended with 
10 ml S1 buffer provided by the manufacturer and then lysed with 10 ml S2 buffer. 
The resultant supernatant was incubated for 10 min at 4 °C before being neutralized 
with 10 ml S3 buffer and subjected to centrifugation again at 12,000 rpm for 45 min 
at 4 °C. Next the supernatant was allowed to be filtered through NucleobondTM ion-
exchange column which was pre-equilibrated with 5 ml N2 buffer. When all volume 
has passed through the column, 12 ml of N3 buffer was being run through the 
column twice. The plasmids were then eluted with 12 ml of N5 buffer followed by 
precipitation with 8.4 ml of isopropanol before being centrifuged at 11,500 rpm for 
30 mins at 4 °C. For the purification process, the plasmids were resuspended with 
1:10 volume 5 M NaCl and 2 volume 95% vol/vol ethanol before being transferred to 
-80 °C for 30 mins. After incubation, the mixture was centrifuged at 14,000 rpm for 
30 mins at 4 °C and the resulting pellet was washed with 70% vol/vol ethanol twice. 
The pellet was allowed to be air-dried before it was resuspended in 100 µl of sterile 
RNAse free water.  
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6 Analysis of DNA by Southern blotting 
For nucleotide analysis, the plasmids were being digested with restriction 
endonucleases (RE) by incubating 25 µl of each plasmid with 2.5 µl of RE buffer and 
0.5 µl of RE for 1 hr at 37 °C. Next 1 µl of DNA loading dye was added to 25 µl of 
RE digestion product before being subjected to 10% agarose gel with 1% ethidium 
bromide (EtBr). When the DNA fragments were well separated, the gel was 
visualized with an ultraviolet illuminator and the nucleotide fragments were 
analysed. 
  
7 Transient transfection of plasmids: 
For transient expression, HCT116 cells grown at 50% confluency in 6-well plate 
transfected with 8 µg of pGFP-LC3 or pCINeoEV or pCINeo+Cat plasmids in 
Optimem1TM medium (Invitrogen Corporation, Carlsbad, CA) without serum using 
the Superfect transfection reagent (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. Briefly, 10 µl of Superfect were mixed with 226 µl of 
plain Mc Coy’s medium and being vortexed for 10 secs. Then 8 µg of plasmid was 
being added to the transfection mixture and being incubated at 37 °C for 20 mins. 
After that, the transfection mixture was added with additional 300 µl of plain Mc 
Coy’s and 500 µl of each transfection mixture was being added drop-wise to each 
well. The plasmids were allowed to be incubated for 48 hours before being subjected 




8 Transient silencing of messenger RNA:  
For knockdown of gene expression, 50 nM siRNA (Beclin1 siRNA, or JNK1/2 
siRNA, or ERK1/2 siRNA, or Atg7 siRNA, or ULK-1 siRNA) was transfected into 
cells in Optimem1TM medium using the Dharmafect1 reagent (Dharmacon) according 
to the manufacturer’s instructions. Briefly, 2 µl Dharmafect1 reagents was added to 
200 µl of Optimem1 and the mixture was vortexed for 10 seconds before being 
incubated for 10 min at 37 °C. In another tube, 50 nM of siRNA was resuspended in 
200 µl of Optimem1. Similarly, this mixture was also vortexed and incubated as the 
same condition as the previous mixture, and being added drop-wise to the first tube. 
Next, 400 µl of the final transfection mix was added drop-wise to the respective well.  
After transfection with the plasmid or siRNA, cells were cultured in 10% serum for 
48 hours before the assessment of protein expression by Western blotting. 
 
9 Drug treatments: 
Various drugs and inhibitors were used in this study as useful tools to investigate 
relevant pathways involved as well as to explore the mechanisms related to C1-
induced cellular responses. The timing and dosage for each drug has been optimized 
and subsequent experiments were repeated by following the exact condition for drug 
treatments to minimize variability in experimental setup. The procedures for drug 
treatments are summarized as follows: 
C1 treatments at various doses were administered according to the methods described 
in the respective figure legends. Catalase, actinomycin D and cycloheximide were 
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added 1 hour while NAC and MG132 were pre-incubated for 2 hours prior to C1 
treatment.  
  
10 Cell viability and tumor colony forming assays: 
Cell viability following drug exposure was determined by the MTT assay as 
described previously. Briefly, 1x106 cells/well were seeded onto 6 well plates and 
exposed to C1 for 18-24 hours before being trypsinized, washed with cold PBS, and 
incubated with MTT [3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide; 
Sigma Aldrich] for 2 hours.  The formazan crystals were then being dissolved with 
Sorenson’s glycine and DMSO (Sigma Aldrich, St. Louis, MO) and absorption was 
measured with a TECAN spectrophotometer at 570nm. For colony forming assays, 
10,000 cells were plated in petri dishes and grown for 2 weeks. The plates were then 
stained with crystal violet solution (Sigma Aldrich, St. Louis, MO) and colonies were 
scored manually as described previously.  
 
11 Western blotting: 
Whole cell protein extracts were isolated using 1 X RIPA lysis buffer (50mM Tris-
HCl, pH 7.4, 150mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1mM EDTA and 
protease inhibitors (Calbiochem, San Diego, CA). Equal amounts of protein from the 
total cell lysates (30 to 120µg/lane) was separated by sodium dodecyl sulfate (10%, 
12% or 15%) polyacrylamide gel electrophoresis gels (SDS-PAGE; BioRad 
Laboratories), transferred to PVDF membrane (BioRad Laboratories) using wet 
transfer (BioRad Laboratories). The membranes were blotted with 1:1000 dilution of 
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the primary antibodies specific for Bax, LC3, Caspase- 9, β-actin, GAPDH, ULK1 
(Santa Cruz Biotechnology), Beclin1, ATG7, ATG12, ATG5, Cytochrome C, JNK, 
p-JNK, c-JUN, p-c-JUN, Bid (Cell Signaling Technology), Caspase 3 (Upstate, 
Millipore Corporation), Caspase 8, Smac, anti-poly(ADP-ribose) polymerase (BD 
Pharmingen) and Catalase (Calbiochem) overnight at 4 °C. After overnight 
incubation with the primary antibodies, the membranes were being washed with 1X 
TBS with 0.1% Tween-20 for 3 times and then blotted again with respective 
secondary isotype specific antibodies tagged with horseradish peroxidase (Thermo 
Scientific Pierce, Rockford, IL). Bound immuno-complexes were detected using 
WEST PICO Chemiluminescence substrate (Thermo Scientific Pierce, Rockford, IL) 
on Kodak films.  
 
12 Immunoflurorescence for GFP-LC3:  
Following transfection with pGFP empty vector or pGFP-rLC3, cells were incubated 
with C1 for 6 to 24 hours and visualized by a fluorescent microscope (Eclipse 
TE2000-S, Nikon) using excitation wavelength of 488nm and emission wavelength 
of 525nm. 
 
13 Propidium Iodide staining for DNA fragmentation:  
Briefly, 1x106 cells/ml were fixed with 70% vol/vol ethanol, and stained with 
propidium iodide (Sigma Aldrich, St Louis, MO) for DNA content analysis. At least 
10,000 events were analyzed by flow cytometry (Coulter EPICS Elite ESP) with the 
excitation set at 488 nm and emission at 610 nm. Histogram data indicating 
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percentage of cells with sub-diploid DNA are shown and are mean ± SD of three 
independent observations. 
 
14 Flow cytometric analysis of intracellular ROS: 
For determination of intracellular H2O2, cells were tripsinized, washed with 1 X PBS 
and loaded with 5 µmol/L of the redox sensitive dye 5-(and-6)-chloromethyl-2-,7-
dichlorofluorescin diacetate (CM-H2DCFDA) (Molecular Probes, Invitrogen 
Corporation) at 37°C for 15 minutes. Then the stained cells were washed again with 
1 x PBS and resuspended with 500 ml of plain medium and analyzed by flow 
cytometry (Coulter EPICS Elite ESP) using an excitation wavelength of 488 nm and 
emission wavelength of 525 nm. CM-H2DCFDA is a cell permeable dye which could 
be cleaved by intracellular asterases to CM-H2DCF to prevent its backflow into the 
extracellular medium. It could be oxidized by intracellular oxidants to yield C-DCF 




ˉ measurement by MitoSox
TM
 RED 
Detection of intra-mitochondrial O2
- was performed by loading cells with the cationic 
redox sensitive probe hexyl triphenylphosphonium cation (TPP+)- HE, otherwise 
known as MitoSoxTM RED MITOCHODNRIAL O2
- INDICATOR (Molecular 
Probes, Invitrogen Corporation) at 37°C for 15 minutes and analyzed by flow 
cytometry (Coulter EPICS Elite ESP) using an excitation wavelength of 590nm and 
emission of 619nm.  At least 10,000 events were analyzed. MitoSoxTM RED is a cell 
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permeable dye which could be targeted to the negatively charged mitochondrial 
membrane whereby the HE moiety could then be oxidized by O2
-. 
 
16 Heavy membrane fractionation:  
HCT116 cells treated with C1 for 6, 12 and 24hrs were suspended in 10 volume of 
Buffer A for 30 min and homogenized with a Dounce Homogenizer (Sartorius AG).  
Homogenates were centrifuged at 300g for 10mins at 4oC.  Supernatants were further 
centrifuged at 25,000g for 45mins at 4oC to collect the mitochondrial pellets.  The 
mitochondrial pellets were lysed in standard 1xRIPA lysis buffer and the 
supernatants were used as the cytosolic fractions. The resultant fractions would then 
be separated by SDS-PAGE followed by Western blotting to determine subcellular 
distribution of various proteins. 
 
17 Subcellular fractionation for nuclear preparation: 
Following drug treatments, HCT116 were harvested from petri dish by tripsinization 
and subjected to centrifugation at 1,500g for 3 min. The pellet was resuspended in 
400 µl of Nuclear Buffer and incubated on ice for 15 min. After that, 25 µl of NP-40 
was added to the cell suspension and vigorous vortexing was carried out for 10 sec. 
The cell suspension was then being centrifuged at 14,000 rpm for 30 sec at 4 °C. The 
supernatant (cytosolic fraction) was transferred to a clear centrifuge tube and stored 
at -80 °C. The pellet containing nuclear fraction was resuspended with 50 µl of ice 
cold Buffer C and incubated for 15 min at 4 °C before being kept at -80 °C. The 
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fractions were then subjected to SDS-PAGE and Western blotting as described in 
Materials & Methods. 
 
18 Electron microscopy: 
Cells were fixed overnight in 2.5% glutaraldelhyde in 0.1M phosphate buffer (pH 
7.2), before being post-fixed in 1% OsO4 for 1 hour. Next, cells were dehydrated in 
ethanol series and embedded in Spurr’s resin.  Ultra thin sections were stained with 
uranyl acetate and lead citrate and observed under a JEOL JEM-1230 transmission 
electron microscope.  
 
19 Buffers and stock solutions used in the study: 
 
Catalase 
Catalase was freshly prepared by weighing out 7000 units/ml and dissolved in plain 
Mc Coy’s medium. 
 
NAC 
NAC was prepared as 2 mM stock was prepared freshly prior to drug treatment. 
SP600125 
SP600125 was prepared as a stock solution of 20 mM by dissolving it with DMSO. 
 
PD98059 
PD98059 was prepared as a stock solution of 20 mM by dissolving it with DMSO. 
MTT 
MTT was freshly dissolved in plain Mc Coy’s medium to a stock concentration of 5 
mg/ml. 
 
Propidium iodide dye 
PI stock solution (50X) was dissolved in sodium citrate buffer (38 mM) to a stock 
concentration of 0.5 mg/ml and kept in 4 °C and prevented from light exposure. 
PI: RNAse A solution was freshly prepared with 1/50 volume of PI and 1/40 volume 






RNAse A was dissolved in 10 mM Tris-HCl (pH 7.5) and 15 mM NaCl to a stock 
concentration of 10 mg/ml and kept at -20 °C. 
 
RIPA lysis buffer 
RIPA lysis buffer was prepared with 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% v/v 
Nonidet P40, 1% v/v deoxycholic acid,  0.1%  v/v SDS, 1 mM EDTA. Before use, 
the buffer was supplemented with protease inhibitors (1 mM PMSF, 10 µg/ml 
Aprotinine, 20 µg/ml Pepstatin A) and phosphatase inhibitors (1 mM NaF, 1 mM 
Na3VO4). 
 
Running Buffer for SDS-PAGE 
Running buffer for SDS-PAGE was prepared by adding 60 g Tris-base 60, 288 g of 
Glycine, 20 g of SDS and dissolved in 2 L of dH2O. 
 
Transfer buffer for western blot: 1X (5L) 
Transfer buffer was prepared by adding 12.1 g Tris-base, 57.84 g Glycine, 1 L 
methanol to a total volume of 5 L with dH2O. 
 
Laemmli loading buffer: 5X (10 ml) 
Tris-HCl pH 6.8 3.1 ml (1 M), SDS 1 g (10%), glycerol 2 ml (20%), β-
Mercapthoethanol 2.5 ml (25%), Bromophenol Blue (BPB) 0.01 g (0.1%), 2.4 ml 
dH2O. 
 
Buffer A for heavy membrane fractionation: 
50 mM PIPES-KOH pH 7.4, 220 Mm mannitol, 68 mM sucrose, 50 Mm KCl, 5 mM 
EGTA, 2 mM MgCl2, 1 mM DTT. Before use, the buffer was supplemented with 
protease inhibitors (1 mM PMSF, 10 µg/ml Aprotinine, 20 µg/ml Pepstatin A) and 
phosphatase inhibitors (1 mM NaF, 1 mM Na3VO4). 
 
Sorenson’s Glycine Buffer 
Sorenson’s Glycine buffer was prepared as 0.1 mM NaCl and 0.1 M Glycine (pH 
10.5) in distilled water and stored at 4 °C. 
 
Buffer A for nuclear fractionation: 
Buffer A for nuclear fractionation was prepared using 10 mM Hepes pH 7.9, 10 mM 
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT and resuspended with dH2O. 
Before use, 0.5 mM of PMSF was added.  
 
Buffer C for nuclear fractionation: 
Buffer C was prepared with 20 mM Hepes pH 7.9, 50 mM NaCl, 1 mM EDTA, 1 







TBS was prepared as 500 ml 1 M Tris HCl (pH 7.4) with 87.6 g of NaCl in 10L of 




TBST was prepared as 2 L TBS with 2 ml of Tween-20 and stored at room 
temperature. 
 
20 Statistical Analysis: 
Experimental differences were tested for statistical significance using Student’s t-




















PART 1: C1 INDUCES CELL DEATH AND MOMP IN HUMAN TUMOR 
CELLS 
 
1.1 C1 induces reduction of cell viability and colony formation in HCT116 
cells  
 Merodantoin (Hereafter referred to as C1) is a small molecule compound with 
a molecular weight of 242. C1 was originally purified from the photooxidation of 
merocyanine 540. The chemical structure of C1 is N,N'-Dibutyl-thio-4,5-
imidazolindion (Figure 4). To explore the death inducing ability of C1, a dose 
response curve against HCT116 human colorectal carcinoma cells was obtained.  To 
do so, cells were treated with increasing concentrations of C1 for 24 hours and 48 
hours, before being harvested for determination of cell viability. Cell viability is 
assessed by MTT assay. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) is a standard colorimetric assay, which capitalizes on the fact that live cells 
contain active mitochondrial reductase enzymes. These mitochondrial enzymes 
catalyze the reduction of MTT dye to an insoluble formazan. The purple formazan 
was solubilized with dimethylsulfoxide (DMSO) and Sorenson’s Glycine buffer into 
a colored solution. Absorbance of this solution was then measured with a 
spectrophotometer at 570 nm. Cell viability was determined by percentage of 
absorbance value with regard to untreated control sample. Exposure of tumor cells to 
increasing concentrations (25-200 µg/ml) of C1 resulted in a dose-dependent 
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decrease in cell viability at 24 hours with the LD50 of ~100 µg/ml (Figure 5). At low 
doses of 25 and 50 µg/ml, there was minimal reduction in cell viability while at 200 
µg/ml, more than 70% of the cells were not viable. The experiment was also 
performed at 48 hours to assess the effect of C1 drug at late time point. However, 
treatment of HCT116 cells by C1 at 48 hours was proven to be highly toxic and 
produced massive cell death regardless of the dose of C1. Therefore, treatment of 
HCT116 cells by C1 for 48 hours did not produce a dose response curve, unlike the 
treatment of 24 hours. This result is not unsurprising considering that cell death 
hallmarks were evident at 18 – 24 hours time point, which will be discussed in the 
next section. Having established the cell killing ability of C1, it is of paramount 
importance to determine whether C1 also retards the long term colony forming 
abilities of tumor cells. This is to ensure that anticancer drugs are not only effective 
in inducing cell death, but also impede the colony formation in long term cultures. 
Thus, cells were treated for 24 hours with 25-100 µg/ml of C1 and long-term colony 
forming ability was assessed after 14 days. Results showed a significant reduction in 
clonogenic ability at 25 and 50 µg/ml and a complete cessation of colony formation 
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Figure 4: Chemical structure and molecular weight of the small molecule 
















         
 
 
Figure 5: C1 induces reduction of cell viability in HCT116 colorectal cells.  
HCT116 cells were treated with increasing concentrations of C1 (25 µg/ml to 100 
µg/ml) for 18 hours and cell survival was assessed by the MTT assay as described in 
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Figure 6: Exposure of HCT116 cells to C1 induces reduction in clonogenic 
ability of tumor cells. Following exposure to C1 for 18 hours, HCT116 cells were 
harvested and the number of cells in each sample was counted. 10,000 cells were 
seeded onto each well of 6-well plates for assessment of colony formation. 2 weeks 
later, wells were stained with crystal violet stain for 15 minutes before being washed 







1.2 C1 triggers MOMP in HCT116 cells 
 Having ascertained that C1 has a potent death inducing ability in tumor cells, 
the mechanisms of C1-induced cell death were investigated. Defects in apoptotic 
pathways have been recognized as one of the prime causes for cancer resistance. To 
assess whether C1 also activates the mitochondrial pathway, the subcellular 
translocation of apoptogenic factors were assessed. Upon incubation with C1 from 6, 
12 to 24 hours, HCT116 cells were being harvested and subjected to homogenization 
and differential centrifugation. The resultant heavy membrane fractions, which are 
enriched with mitochondria as well as the cytosolic fractions were being assessed by 
Western blots. Results showed that incubation of cells with C1 triggered 
mitochondrial outer membrane permeabilization (MOMP) as evidenced by the 
translocation of cytochrome c and Smac, and the reciprocal translocation of Bax and 















                                                         
               










Figure 7: C1 triggers MOMP in HCT116 cells. Cells were treated with C1 (100 
µg/ml) for 6, 12 and 24 hours, and sub-cellular fractions were obtained as described 
in Materials and Methods. Proteins from cytosolic and mitochondrial fractions were 
subjected to Western blot analysis using anti-Bax, anti-Smac, anti-Cytochrome C, 






1.3 C1 triggers efficient caspase processing in HCT116 cells 
 Processing of pro-caspases into active form are important mechanisms to 
ensure maximal activation of both initiator and executioner caspases (Rupinder et al., 
2007). Indeed, efficient processing of caspases by oligomerization has been shown to 
enhance their proteolytic activity (Fuentes-Prior and Salvesen, 2004). Despite this 
fact, many apoptogenic factors may culminate in apoptotic cell death without the 
involvement of caspases. The existence of efficient caspase processing can be 
investigated through analysis of caspase cleavage by Western blot. To determine if 
the major executioner of apoptosis, caspases were being implicated in C1-induced 
cell death, caspases 3, 8 and 9 processing were investigated. Caspase 3 cleavage 
(p19, p17 fragments) was evident following 12 hours of C1 treatment, and peaks at 
24 hours (Figure 8). Similarly, caspase 9 processing followed the same trend as 
caspase 3 (Figure 8). Intriguingly, caspase 8 processing was also detected, but its 
activation profile was similar for both 12 hours and 24 hours time point (Figure 8). 
Collectively, these data suggested an involvement of caspases in the activation of 
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Figure 8: C1 triggers efficient caspase processing in HCT116 cells. Lysates from 
cells treated with C1 (100 µg/ml) for various time intervals were probed for 







1.4 Apoptotic cell death induced by C1 is caspase-dependent 
 To further substantiate the existence of apoptosis in these cells, poly (ADP-
ribose) polymerase (PARP) cleavage was investigated. PARP has been shown to be 
primarily cleaved by caspase-3, one of the major executioner caspases responsible 
for various morphological hallmarks of apoptosis (Nicholson et al., 1995). PARP 
cleavage is also a central morphological hallmark of apoptosis as cleavage of PARP 
into 86 and 24 kDa fragments inactivates the enzyme and results in its loss of DNA 
repair function (Berger and Petzold, 1985). Exposure of HCT116 cells to C1 for 24 
hours resulted in PARP cleavage at 89 kDa (Figure 9). To investigate the 
involvement of caspases in this model, cells were pre-incubated with the pan-caspase 
tetrapeptide inhibitor, zVAD-fmk for one hour before the addition of C1. Total cell 
lysates were then being analysed for PARP cleavage. As seen in Figure 9, zVAD-
fmk treatment completely abolished the effect of PARP cleavage induced by C1.  
 In addition, cell cycle analysis was performed on C1-treated cells. Propidium 
iodide (PI) staining is commonly used to assess cell cycle profile by way of 
intercalation of the PI dye with DNA. The intensity of fluorescence emitted is 
proportional to the amount of dye being incorporated into the DNA and could be 
detected by flow cytometry analysis (Suzuki et al., 1997). Particularly relevant to 
apoptosis are the existence of sub-G1/ sub-diploid population of cells which falls at 
the left side of the G1 peak. The sub-G1 population consists of the cells with 
fragmented DNA. Thus, uptake of PI dye by these cells is much less than cells with 
normal DNA content. To perform cell cycle analysis, cells were being treated with or 
without zVAD-fmk for an hour, followed by C1 treatment for either 24 hours or 48 
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hours. Harvested cells were then being permeabilized and fixed, before being stained 
with PI. Analysis of cell cycle revealed 19% of the cells with sub-G1 population 
following C1 treatment for 24 hours, which was significantly increased to 52% upon 
incubation for 48 hours and blocked in the presence of the pan-caspase inhibitor 
(Figure 10). Taken together, these data demonstrated an existence of caspase-
dependent apoptotic cell death elicited by the novel small molecule, C1, exemplified 
by caspase activation, PARP cleavage, DNA fragmentation and release of 





















                                   
 
                                         
 
Figure 9: PARP cleavage induced by C1 is caspase- dependent. HCT116 cells 
were treated with (A) C1 (50 µg/ml or 100 µg/ml) or (B) in the presence or absence 














Figure 10: C1-induced DNA fragmentation is a caspase- dependent process. 
Cells were treated with C1 (100 µg/ml) in the presence or absence of zVAD (50 µM) 
and cell cycle profiles were obtained by PI staining as described in Materials and 








1.5 zVAD-fmk, but not Necrostatin A, inhibits C1-induced reduction in cell 
viability  
 In this model, apoptotic cell death, as evidenced by PARP cleavage and 
increase in sub-G1 fraction, was dependent on caspase activation. Nonetheless, the 
reduction in cell proliferation may indicate multiple forms of cell death phenotypes. 
Apoptosis may constitute the sole pathway in C1-induced cell death, or it could co-
exist with other modes of programmed cell death. To determine this, cell viability 
assay was carried out by incubating the pan-caspase inhibitor, zVAD-fmk prior to C1 
treatment. Cells pre-treated with zVAD displayed higher survival rate than cells 
treated with C1 alone. Intriguingly, while zVAD inhibited the effect of C1 on PARP 
cleavage and DNA fragmentation (sub-G1), it only partially provided protection from 
C1-induced cell death (Figure 11A). These data indicate that C1-induced cell death 
might involve caspase-independent pathways, in parallel or distinct from apoptosis. 
To investigate that, the effect of the necrosis inhibitor, necrostatin A, on C1-induced 
cell death was evaluated. Necrostatin A was reported to inhibit necrosis by inhibiting 
the loss of mitochondrial membrane potential as well as blocking RIP1 activation. 
Results show that necrostatin A had no effect on C1-induced cell death, thereby 










       
 
Figure 11: zVAD-fmk, but not Necrostatin A, inhibits C1-induced reduction in 
cell viability. (A) HCT116 cells were pre-incubated with zVAD (50 µM) for 1 hour 
before exposure to C1 (100 µg/ml for 18 hours) and survival was assessed by the 
MTT assay. (B) Cells were pre-incubated with necrostatin (50 µM for 1 hour) before 
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PART II: INDUCTION OF NON-CANONICAL AUTOPHAGY BY C1 
 
2.1 Autophagosome formation is a morphological hallmark of C1-treated cells 
 Having shown that zVAD and necrostatin A were unable to rescue cells 
completely from C1-induced cell death, electron microscopic analysis of cell 
morphology following exposure to C1 was performed. HCT116 cells were being 
treated with C1 (100 µg/ml for 12 hours and 24 hours) before being fixed, 
dehydrated and sectioned for EM analysis. Intriguingly, exposure of cells to C1 
resulted in the formation of autophagosomes and autophagic vacuoles, reminiscent of 
autophagy (Figure 12). The appearance of autophagosomes, which are double 
membrane-bound vesicles of 300 – 900 nm in diameter, is one of the morphological 
characteristics of autophagy (Yorimitsu and Klionsky, 2005). As depicted in Figure 

















Figure 12: Autophagosome formation is a morphological hallmark of C1-
treated cells. HCT116 cells were treated with C1 (100 µg/ml) for 24 hours, fixed and 
viewed under an electron microscope as described in Materials and Methods 
(Magnification X 40,000). Arrows indicate the presence of autophagosomes and 





2.2 Detection of LC3II accumulation and translocation to the mitochondria in 
C1-treated cells 
 Several ways of autophagosome measurement exists, and is not limited to 
direct detection of autophagosomal structures via EM imaging. Other methods of 
autophagy analysis include detection of LC3 lipidation on Western blots and 
fluorescent GFP-LC3 imaging. Intrigued by the large amount of autophagosomes 
present in C1-treated cells, it is logical to probe into other mechanistic detail of 
autophagic induction in this system. To gain further insight into the autophagic 
pathway, the increased expression of MAP1 LC3II (herein referred to as LC3II), a 
bona fide marker of autophagy was evaluated. LC3II is the cleaved product of LC3I 
mediated by Atg4, and following the proteolytic cleavage, it is readily conjugated to 
the lipid phosphatidylethanolamine (PE) (Kabeya et al., 2000). In contrast to other 
protein complexes which also localizes to the pre-autophagosomal structures (PAS), 
LC3II accumulates at the intermediate vesicles and also the completed 
autophagosome (Kirisako et al., 1999). Thus, LC3II is widely used as an autophagic 
marker in mammalian system. To assess the lipidation of LC3, increase in LC3II 
protein level was being examined in a time kinetics experiment. Indeed, elevated 
accumulation of LC3II was observed following incubation with C1 in a time-
dependent manner (Figure 13A). Interestingly, LC3II level diminished at 48 hours 
post treatment, which may indicate completion of the autophagic degradation 
process, with accompanying breakdown and recycling of the cargo. Of particular 
note, it was identified for the first time LC3II enrichment in the heavy membrane 
fractions following drug treatment, suggesting its localization to the mitochondria 
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(Figure 13B). This may indicate the presence of mitochondrial engulfment by the 
autophagic vacuoles. 
                                       
 
                                                                                                                                                                   
 









Figure 13: Detection of LC3II accumulation and translocation to the 
mitochondria in C1-treated cells. (A) Lysates of cells treated with C1 (100 µg/ml) 
for 12, 24 and 48 hours were probed for LC3II using a specific antibody (14 kDa) 
that has higher affinity for LC3II than the other LC3 forms. (B) Western blotting 
analysis of LC3II within cytosolic and mitochondrial fractions of cells following 
exposure to C1 for 12 to 24 hours. 
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2.3 C1-treated GFP-LC3 transfected cells display punctate staining reminiscent 
of autophagic phenotype 
 Next, HCT116 cells were transfected with a plasmid encoding GFP-LC3 and 
immunofluorescence was performed following exposure to C1.  GFP-LC3 plasmid is 
a construct of LC3 protein with a fluorescent protein, GFP. GFP-LC3 has been 
widely used as a method to monitor autophagy via fluorescence microscopy. The 
cells which express GFP-LC3 exhibit diffuse green GFP staining, and the 
fluorescence pattern could be converted to punctate staining during the induction of 
autophagy, due to LC3II aggregation on the autophagosomes. To determine 
autophagosome formation, GFP-LC3 or GFP plasmid alone were being transfected 
into the cells with the cationic-lipid mediated delivery method. Drug treatment was 
administered for the indicated time points 48 hours post transfection. Whereas the 
distribution of LC3-GFP in non-treated cells displayed a diffuse pattern, exposure to 
C1 for 6 hours resulted in a green punctate staining, indicative of LC3II 













            
 
Figure 14: C1-treated GFP-LC3 transfected cells display punctate staining 
reminiscent of autophagic phenotype. Cells were transiently transfected with GFP-
Vector or LC3-GFP for 48 hours before exposure to C1 for 24 hours and analyzed 
using a fluorescence microscope. Arrows point to the punctate staining indicating 
LC3 II aggregation into autophagosomes as opposed to diffuse staining in untreated 






2.4 Treatment of HCT116 cells with C1 increases expression of Atg7 and 
conjugation of Atg12-Atg5  
 In order to further examine C1-induced autophagy in greater detail, protein 
expression levels of Atg7, 5, and 12 were also assessed in response to C1 treatment. 
The protein expression of Atg7, a critical E1-like enzyme responsible for the 
conjugation of Atg5 to Atg12 as well as partially involved in the conjugation of 
phosphatidylethanolamine (PE) to LC3 was evaluated. A significant increase in 
expression of Atg7 was observed upon exposure (6-24 hours) of cells to C1 (Figure 
15). Atg12-Atg5 conjugation represents one of the two important ubiquitin-like 
conjugation systems involved in the generation of autophagosomes (Maiuri et al., 
2007). In some systems where free Atg5 could be detected, the amount of conjugated 
Atg12-Atg5 increases in response to autophagic signals. Thus monitoring 
conjugation of Atg12-Atg5 is frequently used as a measurement of autophagy.  In the 
current model, an increase in Atg5 expression in a time dependent manner from 12 
hours to 24 hours, with a concomitant decrease in Atg12 level were being detected 
(Figure 15). The decrease in Atg12 expression at the late time points (12-24 hrs) 
when Atg5 expression was increased is in agreement with similar data indicating 
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Figure 15: Treatment of HCT116 cells with C1 increases expression of Atg7 and 
conjugation of Atg12-Atg5. Following C1 exposure (100 µg/ml) for various time 
points, from 30 minutes to 24 hours, cell lysates were probed for Atg7, Atg5 and 
Atg12 by Western blotting.  Note the decrease in Atg12 and the reciprocal increase in 







2.5 Increase in LC3 Lipidation in response to C1 treatment is a general 
phenomenon across cell lines 
 To provide evidence that the induction of autophagy by C1 was not exclusive 
to HCT116 cells, 9 other cancer cell lines from different lineages were investigated. 
These cells include melanoma M14 cells, lung carcinoma A549, cervical cell HeLa, 
neuroblastoma SHEP-1 and SH-SY5Y, nasopharyngeal carcinoma C666-1, HK-1 
and three different breast cancer cell lines MCF-7, T47D and MDA-MB231 cells. In 
all cell lines LC3II formation were observed in a dose-dependent manner, being 
exposed with C1 from 25 – 200 µg/ml (Figure 16). Notably most of the cell lines 
displayed observable LC3 lipidation when being treated with 100 µg/ml of C1, which 
was in agreement with the effective dose required to induce autophagy in HCT116 
cells. These observations confirmed that C1 is a potent autophagic inducer in a 
variety of tumor cells. Interestingly, across the breast cancer cell lines there were 
varying degrees of LC3II formation with regard to C1 treatment. It appears that 
MCF-7 had the lowest level of LC3II accumulation, followed by T47D while MDA-
MB-231 was most responsive to C1 treatment. This observation is intriguing as both 
T47D and MDA-MB-231 cells are both highly invasive and metastatic cancer cell 









         
 
Figure 16: Increase in LC3 lipidation in response to C1 treatment is a general 
phenomenon across cell lines. Cervical cancer cells HeLa, nasopharyngeal 
carcinoma HK-1, C666-1, breast cancer cells MCF-7, T47D, MDA-MB-231, lung 
carcinoma A549, neuroblastoma cells SHEP1, SH5YSY and melanoma M14 cells 
were treated with various concentrations of C1 for 24 hours and total cell lysates 





2.6 Beclin1 is not involved in C1-induced autophagy 
 Beclin1 was shown to be one of the most important ATG genes, being 
involved in the initial steps of autophagosome formation. Intriguingly, the discovery 
of a non-canonical pathway in autophagy which is not dependent on Beclin1 has 
raised interesting question on the biological role of Beclin1 in the induction of 
autophagy (Scarlatti et al., 2008). In order to address this issue, Beclin1’s role in C1-
induced autophagy was determined. To do so, Beclin1 expression level in total 
lysates was first assessed. Interestingly, despite the formation of autophagosomes and 
increase in LC3II formation, the expression of Beclin1 did not increase significantly, 
but if anything, after 12 hours following drug exposure Beclin1 level was 
significantly reduced in whole cell lysates (Figure 17A). Since protein expression 
level may not always correlate with its activity, the involvement of Beclin1 was 
further investigated by evaluating the effect of siRNA-mediated gene silencing of 
Beclin1 on C1-induced autophagy. Beclin1 mRNA was being silenced with 100 nM 
of siBeclin1 by using the DharmaFECT1 siRNA transfection reagent, after which the 
expression level of Beclin1 and the accumulation of LC3II were being assessed with 
western blotting. Beclin1 expression was efficiently silenced with 100 nm of 
siBeclin1; however knock down of Beclin1 failed to inhibit LC3II accumulation 
induced by C1 (Figure 17B). Similarly when the cell lysates were being assessed by 
the MTT assay, silencing of Beclin1 could not rescue cells from the death triggering 
activity of the small molecule compound (Figure 17C). Collectively, these data argue 
in favor of an existence of a non-canonical autophagy pathway whereby Beclin1 is 
completely dispensable. 
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Figure 17: Beclin1 is not involved in C1-induced autophagy. (A) Lysates from 
cells exposed to 100 µg/ml of C1 for 2, 6, 12, and 24 hours were subjected to 
Western blot analysis using anti-Beclin1. Anti-β-actin was used as the loading 
control. (B) HCT116 cells were transiently transfected with siRNA against Beclin1 
for 48 hours followed by exposure to C1 (100 µg/ml) for 24 hours. Lysates were then 
probed for LC3II using a specific antibody. Knockdown of Beclin1 was confirmed 
by immuno-blotting. GAPDH expression was used as a loading control. (C) Cells 
were transiently transfected with siRNA against Beclin1 for 48 hours and then 
treated with C1 for 18 hours. Survival was assessed by the MTT assay. 
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2.7 Increase in LC3II is dependent on ATG genes 
 To determine whether other crucial components of the autophagic pathway 
were involved in C1-induced autophagy, gene knockdown of ATG7 was performed. 
As Atg7’s presence is integral to two integral conjugation machineries in autophagy 
(Yorimitsu and Klionsky, 2005), silencing of Atg7 is expected to suppress the 
autophagic response. Following 48 hours of siATG7 transfection of HCT116 cells, 
C1 (100 µg/ml) treatment was administered for 24 hours. The resultant cells were 
then harvested for Western blotting. In contrast to the redundancy of Beclin 1, the 
presence of ATG7 siRNA significantly decreased the LC3 II accumulation induced 
upon C1 exposure while the apoptotic signal (PARP cleavage) remained unchanged 
(Figure 18). Corroborating these findings are results obtained with gene knockdown 
of the UNC-51 like kinase (ULK1; mammalian homolog of yeast Atg1), which is 
crucial in controlling the induction stage of autophagy. Similar to the results obtained 
with ATG7 silencing, the presence of ULK1 siRNA inhibited LC3II formation in this 
model but did not have any effect on the processing of PARP (Figure 19).  Taken 
together, these data provided strong evidence that exposure of HCT116 cells to C1 
triggered non-canonical autophagy, but involved the intermediacy of the ubiquitin 
E1-like enzyme Atg7 and ULK1. Interestingly, these findings also suggested that 
retardation of autophagic signals do not affect caspase-dependent apoptosis, 
indicating that these two pathways are mutually exclusive and may operate parallel to 








                 
 
Figure 18: Increase in LC3II is dependent on ATG 7 gene. HCT116 cells were 
transiently transfected with siRNA against ATG7 for 48 hours followed by exposure 
to C1 (100 µg/ml) for 24 hours. Lysates were then probed for LC3II using a specific 
antibody. Knockdown of each gene was confirmed by immuno-blotting. GAPDH 












         
 
Figure 19: RNAi-mediated silencing of ULK1 could revert the increase in LC3 
lipidation in C1-treated cells. HCT116 cells were transiently transfected with 
siRNA against ULK1 for 48 hours followed by exposure to C1 (100 µg/ml) for 24 
hours. Lysates were then probed for LC3II using a specific antibody. Knockdown of 










2.8 Autophagy process mediated by C1 is insensitive to 3-MA treatment 
 The existence of a Beclin1- independent autophagy pathway was reported to 
be refractory to the Class III PI3 kinase inhibitor, 3-methyladenine (3-MA), routinely 
used as a pharmacological inhibitor of canonical autophagy (Yano et al., 2007).  
Class III PI3 Kinase, or hVPS34, is known to positively regulate autophagy by 
generating phosphatidylinositol-3-phosphate (PtdIns(3)P). 3-MA has been shown to 
be a general PI3 kinase inhibitor, in other words, it could inhibit both Class I and 
Class III PI3 kinase activity (Petiot et al., 2000). The two classes of PI3 kinase 
enzymes have vastly different roles, with Class I having a negative regulatory role in 
autophagic sequestration, while Class III actively promotes autophagic sequestration 
(Kondo et al., 2005). That being said, the reason why 3-MA is still being widely used 
as an autophagic inhibitor is because the class III enzymes are usually found to act 
downstream of Class I enzymes. To corroborate the data on non-canonical, Beclin1-
independent autophagy, 3-MA pre-treatment for 1 hour (5 or 10 mM) was being used 
to inhibit the autophagic process, prior to addition of C1 for 18 hours.  Indeed, a 
priori treatment of cells with 3-MA (5 or 10 mM) had virtually no effect on LC3II 













                               
 








Figure 20: Autophagy process mediated by C1 is insensitive to 3-MA treatment. 
HCT116 cells were pre-incubated with 3-MA (5 or 10 mM) for 1 hour before 
exposure to 100 µg/ml of C1 for 18 hours.  Lysates were then immuno-blotted with 








2.9 Inhibition of caspase activity does not affect LC3 lipidation elicited by C1 
 The interrelationship between autophagy and apoptosis is a complex issue. 
Despite the many experimental endeavours made in addressing this issue, the 
existence of a link between autophagy and apoptosis remained controversial. 
Pertaining to this, the findings presented in the previous section suggested that 
inhibition of autophagy did not affect apoptotic outcome. In order to ascertain that 
apoptosis and autophagy is mutually exclusive, the reverse experiment was 
conducted. Inhibition of caspases by pharmacological inhibitor zVAD, caspase 3 or 
caspase 9 inhibitors was performed to investigate their effects on LC3II induction. 
Pre-treatment of HCT116 cells with these inhibitors did not affect the level of LC3 
lipidation as assessed by Western blot, despite their effectiveness in the prevention of 
PARP cleavage induced by C1 (Figure 21). These results suggested that blocking the 
apoptotic pathway did not alter the autophagic response, and thus strongly 
recommend that the two integral cellular pathways are mutually exclusive to each 
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ZVAD - - +             +             - - - -
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Figure 21: Inhibition of caspase activity does not affect LC3 lipidation elicited 
by C1. Cells were pre-incubated with zVAD (50 µM) or caspase 3 inhibitor (DEVD; 
20 µM) or caspase 9 inhibitor (LEHD; 20 µM) followed by treatment with 100 µg/ml 
of C1 for 24 hours.  Cell lysates were probed for cleavage of PARP and LC3II 







PART III: MODULATION OF AUTOPHAGY AND APOPTOSIS BY ROS 
 As discussed previously in the Introduction session, a complex relationship 
between ROS and various cellular processes existed. Unsurprisingly, the intracellular 
redox status has also been intricately linked to apoptosis and autophagy. Given the 
close interplay between ROS, autophagy and apoptosis, it was a logical progression 
to examine the role of ROS in the activation of cellular signaling pathways by C1. 
  
3.1 C1 triggers mitochondrial superoxide production in HCT116 cells 
 In order to determine the relevance of ROS in this system, intracellular ROS 
production was being assessed with redox-sensitive dye. To do so, a fluorescent 
probe, MITOSOXTM Red, was being used to measure mitochondrial O2
•ˉ level 
following incubation with C1 (15 min, 1hr, 3hr, 6hr).  MITOSOXTM Red selectively 
detects mitochondrial O2
•ˉ as it is specifically targeted to the mitochondria of live 
cells. MITOSOXTM Red is cell permeable and once inside the mitochondria, it will 
be oxidized by O2
•ˉ and emits red fluorescence, with emission wavelength at 510 nm 
and excitation at 580 nm. This dye is also specific to O2
•ˉ as it is less prone to 
oxidation by other ROS molecules. Following incubation of MITOSOXTM Red (5 
µM) for 15 minutes, HCT116 cells are being analyzed with the Fluorescence 
Activated Cell Sorter (FACS). Results showed a significant increase in mitochondrial 
O2
•ˉ  levels, as early as 15 minutes post-treatment, which was sustained for 1 hour 
and began to decrease at 3 hours (Figure 22), indicative of an existence of 
mitochondrial O2






                        
           
 
 
Figure 22: C1 triggers mitochondrial superoxide production in HCT116 cells.  
1X106 cells were incubated with 100 µg/ml of C1 for 15 min to 6 hours and intra-
mitochondrial O2
•ˉ was determined using the fluorescent dye MitoSoxTM RED 
Mitochondrial O2










3.2 Increase in intracellular H2O2 production following C1 treatment in 
HCT116 cells 
 As O2
•ˉ does not readily cross membranes, it is highly unlikely that the 
mitochondrial O2
•ˉ detected by MITOSOXTM Red could transverse from the 
mitochondria to the cytosol and thereby eliciting its downstream signaling effect. 
Moreover, the presence of MnSOD in the mitochondria could mediate the conversion 
of O2
•ˉ to H2O2.  Being a polar molecule, H2O2 can diffuse within the cells in vivo, 
and has also been shown to transverse the membrane water channels, aquaporin 
(Henzler and Steudle, 2000). To confirm the presence of ROS in the cells, the redox-
sensitive probe, CM-DCHF-DA is utilized in this study. CM-DCHF-DA is cell 
permeable and once it enters live cells, it can be hydrolysed by cellular esterases to 
form DCFH. Oxidation of DCFH by cellular oxidants leads to the formation of 
fluorescent DCF (Halliwell and Whiteman, 2004), which could be detected by flow 
cytometry. Incubation of HCT116 cells with C1 at various time points (15 min to 3 
hours) resulted in the right-ward shift in fluorescence, indicating an increase in 
intracellular ROS production (Figure 23). Moreover, treatment of 100 µg/ml of C1 
for 6 hours resulted in a less significant fluorescence shift, as compared to 3 hours of 
C1 treatment at the same dosage (Figure 23). These results were indicative of an 
early burst of ROS production, which could not be sustained for a prolonged time. 
 An important cautionary note in working with DCFDA probe is that it is a 
measurement of general ROS production, and is not exactly specific for any single 
type of oxidant. Many ROS/RNS such as H2O2, OH
•
 and ONOO¯ can oxidize 
DCFDA, and the extent of oxidation is also dependent on other factors, such as the 
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intracellular metal ions concentrations (Halliwell B, 2007). To circumvent this 
problem, catalase was used in conjunction with C1 treatment to check for the 
specificity of ROS produced. Catalase is a specific antioxidant which converts H2O2 
to water and ground-state O2 through the dismutation reaction. As shown in Figure 
23, pre-incubation of catalase (7000 units/ml) for 15 minutes reverted the production 
of ROS induced by C1, indicating that the signal was due to H2O2 generation.   
 Apart from catalase, another important type of enzyme which could remove 
intracellular H2O2 is the peroxidase. N-acetyl-L-cysteine (NAC) was typically used 
as an H2O2 scavenger. NAC can be hydrolysed to cysteine, which is the precursor of 
gluthathione (GSH). In addition, the antioxidant properties of NAC has also 
attributed to its ability to scavenge H2O2 directly (Halliwell B, 2007). To test out the 
effect of removing H2O2 in the system, NAC (200 µM) was pre-incubated with the 
cells for 2 hours to remove the oxidants, followed by C1 treatment. Indeed, the 
existence of NAC suppressed the production of ROS triggered C1, similar to the 















      
 
 
Figure 23: Increase in intracellular H2O2 production following C1 treatment in 
HCT116 cells. HCT116 cells (1X106) were treated with C1 (100 µg/ml) at varying 
time points. Subsequently intracellular H2O2 was detected by DCHF-DA loading and 
analyzed by flow cytometry as described in Materials and Methods. Data are 













   
 
 
Figure 24: Exogenous addition of catalase and NAC abrogated C1-induced ROS 
production. HCT116 cells were pre-incubated with catalase (7000 units/ml) for 1 
hour or NAC (200 µM) for 2 hours before treatment with C1 (100 µg/ml for 3 hours) 
and intracellular H2O2 was determined by flow cytomtery using DCHF-DA loading. 
Data are representative of 3 different independent results. (Figure legend: Solid fill: 






3.3 Transient overexpression of human catalase suppresses C1-induced ROS 
production 
 One of the important aspects of this thesis is based on the ability of C1 drug 
to generate intracellular ROS. Thus, multiple ways of scavenging ROS ought to be 
performed to show a direct correlation between the production of ROS and its role in 
modulating the cell death signaling pathways. While exogenous addition of catalase 
to the culture medium is a good way to check for H2O2 production, this method may 
not be the most effective way in scavenging H2O2. Catalase itself is a large protein of 
approximately 256 kDa and is unable to enter the cells to scavenge the intracellular 
H2O2. Thus, exogenous addition of catalase results in the localization of catalase in 
the extracellular milleu, and will only react with H2O2 which diffuses out from inside 
the cell, thereby lowering the intracellular amount of H2O2. Often, overnight 
incubation of catalase powder into the cells resulted in reduced activity of this 
compound due to its degradation. To circumvent this problem, an array of catalase 
doses have been tested out to synchronize the ideal dose for short term and long term 
assays, and the final dose has been fixed at 7000 units/ml of catalase concentration. 
In addition, in search of a more effective way in lowering intracellular H2O2 level, 
cells were transiently transfected with a plasmid encoding human catalase gene and 
exposed to C1. Cells transfected with pC1Neo empty vector exhibited an increase in 
ROS production, in both C1-treated and H2O2-treated cells as compared to the 
untreated controls. In contrast, catalase-overexpressing cells were markedly resistant 




   
 
                        
 
 
Figure 25: Transient overexpression of human catalase abrogated C1-induced 
ROS production. ) HCT116 cells were transiently transfected with 8 µg of 
pCINeoEV or pCINeo+CAT for 48 hours and treated with C1 (100 µg/ml for 3 
hours) and intracellular H2O2 was determined by flow cytometry analysis. The 
catalase protein expression level was shown on the top left panel and depicts 




3.4 Catalase pre-treatment or overexpression confers protection against C1-
mediated PARP cleavage 
 After determining the ability of C1 in generating intracellular ROS, the next 
logical question is whether the production of ROS was integral in the execution of 
cell death. To do this, inhibition of ROS production was performed by way of an 
ROS scavenger to lower the intracellular ROS and also through a more specific 
method of lowering intracellular H2O2, by transient over-expression of catalase in the 
cells. Indeed, catalase pre-incubation as well as transient overexpression of plasmid 
containing human catalase gene inhibited C1-induced PARP cleavage, a marker of 
caspase 3 activation (Figure 26). These data demonstrated the critical role of ROS in 
the induction of apoptosis by C1, lending credence to an antitumor role of ROS by 
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Figure 26: Catalase pre-treatment or Overexpression conferred protection 
against C1-mediated PARP cleavage. HCT116 cells were pre-incubated with 
catalase (7000 units/ml for 1 hour) or were transiently transfected with pCINeoEV or 
pCINeo+CAT before exposure to C1 (100 µg/ml for 24 hours), and total cell lysates 





3.5 Antioxidants pre-treatment or catalase overexpression inhibits LC3II 
accumulation induced by C1 
 Having observed the involvement of ROS in C1- induced apoptotic signaling, 
the link between ROS and autophagy was investigated. To that end, the effect of 
scavenging ROS on C1-induced LC3II formation was assessed. Similar to apoptotic 
assays, pre-incubation of ROS scavengers, catalase and NAC were performed as 
described previously. Following these assays, catalase overexpression was also 
carried out in order to further affirm the role of ROS in terms of autophagic 
regulation. Results showed that addition of exogenous catalase or its transient 
overexpression as well as pre-incubation of cells with NAC significantly blocked 
LC3II accumulation induced by C1 (Figure 27).  These data strongly suggest the 
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Figure 27: Antioxidants pre-treatment or catalase overexpression inhibits LC3II 
accumulation induced by C1. Cells were pre-incubated with catalase (7000 units/ml 
for 1 hour) (A) or NAC at 200 µM (B) or were transiently transfected with 
pCINeoEV or pCINeo+CAT (C) before exposure to C1 (100 µg/ml for 24 hours), 
and total cell lysates were probed for LC3II accumulation by Western blotting. 




3.6 C1 induces ERK and JNK phosphorylation with a concomitant decrease 
in MKP1 protein expression 
 ROS has been shown as a potent regulator of MAP kinase family members 
(Kamata et al., 2005; Temkin and Karin, 2007; Westwick et al., 1994). Intrigued by 
the robust activation of ROS in our system, activation of MAPK family members 
was investigated. Firstly, phosphorylation of ERK was detected in a time-dependent 
manner, which peaked at 3 hours and subsided at late time points (Figure 28A). In 
addition, JNK phosphorylation at Thr 183 and Tyr 185 was assessed in whole cell 
lysate from C1-treated cells (0.5 to 24 hours).  Robust activation of JNK 
(phosphorylation) was detected as early as 30 minutes and was sustained for 24 hours 
after the stimulus, while no detectable difference in total JNK levels was observed 
(Figure 28A). Stimulated by these findings, the involvement of downstream effectors 
of JNK activation, in particular the transcription factor c-Jun was investigated. c-Jun 
is phosphorylated by JNK at Ser-73 and Ser-63 residues. Therefore, a kinetic analysis 
of c-Jun phosphorylation by Western blotting in total cell lysates was performed. 
Indeed, total c-Jun levels as well as phosphorylation at Ser-73 residue were detected 
as early as 30 minutes upon C1 treatment and persisted throughout the time course of 
24 hours (Figure 28A). MKP1, the downstream inhibitory phosphatase of MAPK had 
been shown to be an important determinant in JNK-induced cell death (Kamata et al., 
2005). Sustained JNK activation was suggested to be due to MKPs oxidation by 
ROS. It is thus highly likely that prolonged JNK activation induced by C1 is linked 
to a concomitant decrease in MKP1 protein level. Indeed, an examination on MKP1 
level revealed a significantly lower MKP1 level in C1-treated cells (Figure 28B). 
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Figure 28: C1 induces phosphorylation of JNK, c-Jun and ERK kinases as well 
as decrease in MKP1 protein expression. HCT116 cells were exposed to 100 µg/ml 
of C1 for the indicated time points and   total cell lysates were subjected to Western 
blotting for the detection of (A) phospho-JNK, total JNK, phospho-c-JUN, phospho-





3.7 Inhibition of ROS production decreases JNK and ERK phosphorylation 
Having shown earlier that JNK and ERK were robustly activated by C1 and 
that ROS production is a critical signal for autophagy and apoptosis, the impending 
question is whether ROS production and MAPK activation is linked in any way. As 
ROS has been shown to be the activating signal for Map kinases, the connection 
between C1-induced ROS production and Map kinase activation was first 
investigated. To do so, the effect of scavenging ROS on C1-induced activation of 
MAP kinases and c-Jun was analyzed. Exogenous addition of antioxidants was first 
performed to determine the sensitivity of Map kinases to ROS inhibition. For catalase 
pre-incubation, the dose for catalase powder was fixed at 7000 units/ml which was 
the same for all other catalase experiments. Cell lysates were then harvested 3 hours 
post incubation with C1, which correlates to their maximal activation time point. 
Figure 5B showed that the presence of catalase (7000 Units/ml) abrogated C1-
induced JNK, ERK and c-Jun phosphorylation (Figure 29A and 29C). Similar results 
were obtained upon pre-incubation of cells with NAC or upon transient transfection 
of cells with human catalase gene (Figure 29B). Taken together, these findings 
clearly highlighted the involvement of ERK and JNK in the biological activity of C1 
and strongly implicated ROS in this signaling pathway.  
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Figure 29: Inhibition of ROS production decreases JNK, c-Jun and ERK 
phosphorylation. Cells were pre-incubated for 1 hour with 7000 units/ml of catalase 
or 200 µM NAC (A) or transiently transfected with pCINeoEV or pCINeo+CAT (B) 
before exposure to C1 (100µg/ml for 3 hours). Total cell lysates were probed for the 
detection of phospho-JNK and phospho-c-JUN by Western blotting. GAPDH and β-
actin were used, respectively as the loading control. (C) Cells were pre-incubated for 
1 hour with 7000 units/ml of catalase before being assessed for phospho- ERK level. 
β-actin was used as the loading control.  
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PART IV: ERK AND JNK ACTIVATION ARE INTEGRAL IN THE 
MODULATION OF CELL DEATH AND AUTOPHAGY 
 
4.1 The presence of ERK inhibitor and JNK inhibitor protect against C1-
induced cell death 
Having shown that ERK and JNK were downstream targets of ROS which 
were both activated following C1 exposure, the next logical step would be to dissect 
the physiological functions brought about by the activation states of these MAPKs. 
 One of the predominant effects of C1 on tumor cells was the execution of cell 
death signaling pathway. To investigate on this, the ability of pharmacological 
inhibitors of ERK and JNK in affecting the cell death read outs was first carried out. 
For the inhibition of ERK, a cell permeable inhibitor, PD98059 was being utilized in 
this system. PD98059 is a specific MEK1 inhibitor and has been shown to be 
selective in the suppression of ERK signaling pathway. MEK1 is the specific 
MAPKK for ERK activation by inducing phosphorylation of Thr and Tyr residues at 
the activation loop of the kinase domain. PD98059 exerts its inhibitory effect by 
binding to inactive form of MEK1 and thus, preventing MEK1 from being activated 
by upstream regulators (Rosen et al., 1994). A dose response analysis of PD98059 
was first carried out to establish the effective dose for ERK inhibition. Though the 
recommended IC50 dose of PD98059 for the inhibitory activity against MEK1 are 
around 5-10 µM, a dose response experiment is critical due to cell line variations. To 
perform the dose response experiment, HCT116 cells were being incubated with 
various doses of PD98059 (5 – 20 µM) for one hour prior to C1 treatment of 3 hours. 
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It was determined that 20 µM of PD98059 for 1 hour is most effective in inhibiting 
ERK phosphorylation (Figure 30A).  
Similarly, SP600125 was being selected as the pharmacological inhibitor 
against JNK. SP600125 (MW=220) is a reversible, competitive inhibitor of JNK with 
a high selectivity against JNK kinase (Bennett et al., 2001). It was shown to be a 
potent inhibitor of JNK which blocks the phosphorylation of various JNK targets, 
including c-Jun and Cox-2 (Bennett et al., 2001). To establish the effective dose for 
JNK inhibition, SP600125 at two different doses was incubated for one hour 
followed by C1 addition. c-Jun phosphorylation was used as a read out for JNK 
activation and 5 µM of SP600125 was selected for future experiments for JNK 
inhibition (Figure 30B). 
 Next, the effect of the respective ERK and JNK inhibitors on cell death was 
being investigated. Inhibition of JNK activity partially protected against C1-induced 
reduction in cell proliferation (Figure 31). Intriguingly, as compared to SP600125, 
PD98059 was found to be much more effective in the rescue of cell death (Figure 
31). The conventional dogma has established that JNK and ERK mainly display 
opposing roles in terms of cell death regulation, with JNK being mainly involved in 
cell death while ERK generally have an anti-apoptotic characteristic. Nevertheless, 
the results in this study suggested that ERK could also act as a potent cell death 
mediator. In fact, the inhibitory effect brought about by ERK inhibition was much 
more pronounced than inhibition of JNK. To further study this, the effect of Map 
kinases inhibition on long term cultures were also assessed. Here, a similar trend was 
depicted; while JNK inhibition significantly rescued the reduction in colony 
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formation triggered by C1, ERK suppression resulted in a more dramatic effect on 
cellular proliferation (Figure 32). To ascertain that Map kinases not only affect 
general cell proliferation and colony formation but also specifically mediate 
apoptotic cell death, the same experiment setting were repeated and tested for PARP 
cleavage via western blotting. Indeed, JNK and ERK inhibition significantly reduced 
the extent of PARP cleavage induced by C1 treatment (Figure 33). Taken together, 
these results indicated an integral regulatory role of the Map kinases, ERK and JNK 



















                         
                            
 
Figure 30: Establishment of effective dose for Map kinase inhibition. Cells were pre-
incubated with (A) PD98059 (PD) or (B) SP600125 (SP) for 1 hour at various doses 
as indicated prior to C1 treatment (100 µg/ml for 3 hours). Activation profile of ERK 










            
 
Figure 31: The presence of ERK inhibitor and JNK inhibitor protected against 
C1-induced reduction in cell proliferation. Cells were pre-incubated with 
SP600125 (SP; 5 µM) or PD98059 (PD; 20µM) for 1 hour before treatment with 100 
µg/ml of C1 for 24 hours and cell survival (MTT assay) was determined as described 
in Materials and Methods. 
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Figure 32: Inhibition of JNK and ERK effectively enhance clonogenic activity of 
C1-treated cells. HCT116 cells were pre-incubated with (A) SP600125 (SP; 5 µM) 
or (B) PD98059 (PD; 20 µM) for 1 hour before treatment with 100 µg/ml of C1 for 
24 hours and tumor colony formation were determined as described in Materials and 
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Figure 33: JNK and ERK inhibitors decrease the extent of PARP cleavage in 
C1-treated cells. HCT116 cells were pre-treated with JNK inhibitor, SP600125 (SP; 
5 µM) or ERK inhibitor PD98059 (PD; 20 µM) for 1 hour before treatment with 100 
µg/ml of C1 for 24 hours. Subsequently total cell lysates from these cells were 
probed for cleavage of PARP by Western blotting. 
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4.2 Pharmacological inhibition of ERK and JNK effectively suppress 
autophagic hallmarks in tumor cells 
Given that exposure of cells to C1 resulted in simultaneous induction of 
autophagy and apoptosis, the next question is whether ERK and JNK activation were 
also central to the autophagic inducing activity of C1. To that end, recent evidence 
has implicated JNK activation in autophagy (Yu et al., 2004). Indeed, pre-incubation 
of cells with the JNK inhibitor SP600125, and ERK inhibitor PD98059, respectively, 
significantly blocked LC3II formation induced by C1 (Figure 34). Importantly, 
inhibition of JNK also reduced the increase in Atg7 expression (Figure 34). These 
data point to a central role for JNK and ERK activation downstream of ROS 
production in the induction of autophagy and apoptosis upon exposure of cancer cells 
to C1. In addition, the effect of JNK inhibition on autophagy was assessed by 
electron microscopy. Indeed, in addition to suppression of LC3 II, SP600125 also 
reduced the amount of autophagic vesicles (autophagosomes and autophagic 
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Figure 34: JNK and ERK inhibitors suppress LC3II accumulation induced by 
C1. HCT116 cells were pre-treated with (A) JNK inhibitor, SP600125 (SP; 5 µM) or 
(B) ERK inhibitor PD98059 (PD; 20 µM) for 1 hour before treatment with 100 µg/ml 
of C1 for 24hours. Subsequently total cell lysates from these cells were probed for 










          
 
 
Figure 35: Pre-incubation of JNK inhibitor attenuates autophagosome 
formation in HCT116 cells. Cells were pre-incubated with SP600125 (SP; 5 µM for 
1 hour) before exposure to C1 (100 µg/ml for 24 hours) and then were fixed and 










4.3 RNAi- mediated silencing of ERK inhibits PARP cleavage and LC3 
lipidation in HCT116 cells 
 In view of the fact that pharmacological inhibition of a cellular target may not 
be the best experimental model to work with, it is integral to show inhibition of a 
certain pathway by way of RNAi-mediated gene silencing. In this regard, knockdown 
of ERK mRNA is not only able to corroborate the inhibitor studies; it will also 
provide greater insights into the molecular mechanisms of ERK-elicited cellular 
responses. In accordance to the inhibitor studies, silencing of both ERK1 and ERK2 
genes proved to be effective in the suppression of PARP cleavage induced by C1 
(Figure 36). These data highlight the essentiality of ERK1 and ERK2 genes in 
controlling the apoptotic cell death pathway. In addition, the effect of silencing ERK 
on LC3 lipidation was also investigated. The data suggested that ERK2 silencing was 
able to abrogate LC3II accumulation, while silencing of ERK1 had no appreciable 
















       
 
 
Figure 36: RNAi- mediated silencing of ERK inhibit PARP cleavage and LC3 
lipidation in HCT116 cells. Cells were being silenced with ERK1, ERK2 or 
scrambled siRNA according to Materials & Methods, and allowed to recover for 48 
hours post transfection. Cells were then subjected to C1 treatment for 18 hours before 









4.4 RNAi- mediated silencing of JNK also inhibit PARP cleavage and LC3 
lipidation in HCT116 cells 
 Similarly, JNK silencing was also performed to further investigate its effect 
on apoptosis and autophagy. JNK silencing was carried out by using the 
DharmaFECT1 transfection reagent and C1 treatment (100 µg/ml for 18 hours) was 
administered 48 hours post-transfection. Successful knockdown of JNK was 
confirmed by expression level of total JNK protein (Figure 37). The findings suggest 
that silencing of JNK inhibited PARP cleavage, corroborating the effects of 
mitigating cell death via pharmacological inhibition of JNK (Figure 37). On the other 
hand, siJNK also rendered the cells more resistant to autophagy as assessed by LC3II 

































Figure 37: RNAi- mediated silencing of JNK inhibits PARP cleavage and LC3 
lipidation in HCT116 cells. Cells were being silenced with JNK siRNA or 
scrambled siRNA according to Materials & Methods, and allowed to recover for 48 
hours post transfection. Cells were then subjected to C1 treatment for 18 hours before 
being harvested and analysed by western blot by using PARP and LC3II specific 
antibodies. Expression of total JNK was probed to assess for successful silencing 







4.5 Inhibition of mRNA and protein synthesis attenuates LC3II 
accumulation 
 To provide further insights into the operational mechanisms on the autophagy 
pathway, the effect of transcriptional and translational inhibition was evaluated. To 
inhibit mRNA synthesis, actinomycin D was used to block the transcription of DNA. 
Actinomycin D is able to bind to DNA at the transcription initiation complex and 
thereby, preventing elongation of DNA strand by RNA polymerases (Sobell, 1985). 
Similarly, cycloheximide was utilized to block protein synthesis in the cells by way 
of inhibiting translational elongation. These inhibitors were pre-incubated in the cells 
for 1 hour to allow their inhibitory effect to take place prior to C1 addition for 18 
hours. Results demonstrated that both actinomycin D and cycloheximide were able to 
suppress LC3II accumulation induced by C1 (Figure 38). This is suggestive of the 
involvement of protein synthesis in modulating an autophagic response in C1-treated 
cells. Furthermore, these data corroborated the earlier findings on the activation of a 













                    
 
                
Figure 38: Inhibition of mRNA and protein synthesis attenuates LC3II 
accumulation. HCT116 cells were being treated with (A) mRNA synthesis inhibitor, 
actinomycin D (AD) or (B) protein synthesis inhibitor, cyclohexamide (CHX) for the 
indicated doses prior to C1 treatment at 100 µg/ml for 18 hours. Harvested cells were 







4.6 C1 induces translocation of JNK to the nucleus 
 One of the major effects of JNK on cellular homeostasis is due to its ability to 
activate transcription factors. In accordance to this, c-Jun phosphorylation was 
detected in response to C1 treatment, implicating that JNK directly activates c-Jun. 
To test out whether JNK’s ability in activating transcription factors is mediated by its 
translocation into the nucleus, subcellular distribution of JNK was being assessed by 
Western blot. In order to so, subcellular fractions of nuclear-rich extracts and 
cytosolic fractions were obtained by homogenization and differential centrifugation 
according to an established protocol, as described previously. As with most 
fractionation procedures, the purity of the individual fractions need to be stringently 
maintained to avoid contaminants carried over from different fractions. It is thus of 
utmost importance to optimize the existing standard protocols to better suit respective 
cell lines and model systems. In addition, the purity of the fractions was also assessed 
by using resident nuclear protein, PARP. Results showed that JNK’s translocation 
from the cytosol to the nucleus was being detected in C1-treated cells, in a time 














             
 
Figure 39: C1 induces translocation of JNK to the nucleus. HCT116 cells were 
treated with C1 (100 µg/ml) for various time points from 1 hour to 6 hours before 
being subjected to differential centrifugation and subcellular fractionation. The 
resultant cytosolic and nuclear fractions were assessed by Western blots to determine 
JNK’s distribution in these compartments by using a specific antibody against 
phosphorylated JNK. Detection of PARP was performed as a purity control and β-






4.7 PD98059 effectively inhibits cytochrome c and bax translocation in C1-
treated cells 
 In the quest to explore the mechanisms of ERK-dependent apoptotic cell 
death, mitochondrial pathway of apoptosis was being investigated. A heavy 
membrane fraction, being enriched with mitochondria was being obtained following 
PD98059 pre-treatment and C1 exposure. This heavy membrane fraction, together 
with the cytosolic fraction were being analysed concurrently on Western blot to 
assess any changes in the subcellular distribution of bax and cytochrome c. It was 
observed that C1 induced efficient bax translocation from the cytosolic fraction to the 
mitochondria, with a reciprocal translocation of cytochrome c (Figure 40). More 
importantly, inhibition of ERK activity by PD98059 almost completely abolished the 
translocation of these apoptogenic factors. These data indicated that the effects of 

















                     
 
Figure 40: PD98059 effectively inhibits cytochrome c and bax translocation in 
C1-treated cells. PD98059 (PD, 20 µM) was added to HCT116 cells for an hour 
followed by C1 incubation for 18 hours. Cell lysates were being subjected to 
subcellular fractionation to obtain cytosolic fraction and heavy membrane fraction, 
which is enriched with mitochondria. These fractions were being used for Western 
blotting for the detection of cytochrome c and bax with their respective antibody as 
described in Materials & Methods. VDAC was used to assess the purity of the 






4.8 Pharmacological inhibition of ERK also rescued C1-induced reduction in 
cell viability in MDA-MB-231 cells, but not in MCF-7 cells 
 The major effects in inducing autophagy and apoptosis by C1 were mediated 
by ERK, and attenuation of ERK signaling effectively abrogated both signaling 
pathways. To confirm that the integral role of ERK in cell death is not limited to one 
specific cell line, two other breast cancer lines were being tested for the sensitivity to 
ERK inhibition by PD98059. In order to circumvent the probability of cell line 
variations, dose response analysis was carried out once again to select the effective 
dose for these breast cancer cells. In order to assess cell survival, PD98059 (5 µM, 10 
µM, 20 µM) was pre-incubated for an hour before C1 incubation for 18 hours, 
followed by MTT assessment as per described in materials and methods. It was 
found that PD98059 effectively blocked cell death induced by C1 in MDA-MB-231 
cells, while MCF-7 was completely refractory to PD98059 treatment (Figure 41). 
These results suggest that ERK inhibition could effectively inhibit cell death in tumor 
cells of different lineages; however, it raised an interesting question on the 
insensitivity of MCF-7 cells to the same treatment. An analysis of the three cell lines 
used in this study revealed an inherent difference of the Ras status. Interestingly, both 
HCT116 and MDA-MB-231 cells harbour oncogenic Ras mutation, while MCF-7 
contains normal Ras gene. Moreover, the indication that PD98059 is only effective in 
systems with oncogenic Ras status could have direct implication in anticancer 
therapy.   
 131
                                                                                                      
 
Figure 41: Pharmacological inhibition of ERK rescued C1-induced reduction in 
cell viability in MDA-MB-231 cells, but not in MCF-7 cells. (A) MDA-MB-231 
and (B) MCF-7 breast cancer cells were pre-treated with various doses of PD98059 
(PD; in µM) for an hour, before being exposed to C1 for 18 hours. Cell survival was 
then assessed by MTT assay. 
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4.9 A possible mechanism of ERK-mediated LC3 lipidation: Involvement of 
p53 
 
4.9 C1 induces p53 downregulation in HCT116 cells 
 Since its discovery nearly 30 years ago, p53 has been unequivocally proven to 
be one of the most prominent tumor suppressors that are frequently mutated in 
human tumors.  In order to assess the role of p53 in the current model, a protein 
expression profile of p53 was analysed following C1 treatment. It is intriguing to find 
out that p53 expression was reduced when the cells were exposed to C1, in a time- 
dependent as well as dose-dependent manner. Reduction in p53 protein expression 
was most prominent at late time points, ranging from 12 to 24 hours (Figure 42). As 
HCT116 harbours wild type p53 alleles, this result could indicate a dispensable role 

















            
                     
                        
 
Figure 42: C1 induces p53 downregulation in HCT116 cells. p53 expression was 
verified by western blot following C1 treatment at various time points, (A) from 30 










4.10 Downregulation of p53 protein expression could be restored by pre-
treatment of proteasomal inhibitor 
 Previously, depletion of p53 has been associated with the activation of murine 
double minute 2 (MDM2) , an E3 ubiquitin ligase which mediates p53 ubiquitination 
and subsequently, targeting p53 to the proteasomal degradation pathway. To verify 
that loss of p53 in C1-treated cells was attributed to proteasomal degradation, a 
specific proteasomal inhibitor, MG132, was utilized to investigate this. MG132 is a 
specific and cell-permeable inhibitor of proteasome, which could impair the 
degradation of ubiquitin-conjugated proteins. By pre-incubating the cells with two 
different doses of MG132 (1.25 µM, 2.5 µM) for 2 hours, loss of p53 expression 
induced by C1 was completely restored (Figure 43). This result indicated that 
downregulation of p53 protein level elicited by C1 was intricately linked to the 
















                   
 
                  
 
Figure 43: Downregulation of p53 protein expression can be restored by pre-
treatment of proteasomal inhibitor. HCT116 cells were pre-incubated with the 
proteasomal inhibitor, MG132 (1.25 µM, 2.5µM) for 1 hour before being triggered 
with C1 (100 µg/ml) for 18 hours. Cell lysates were harvested by tripsinization 
before being subjected to SDS-PAGE and Western blotting. p53 expression level was 










4.11 Inhibition of proteasomal degradation impedes LC3II accumulation 
induced by C1 
 Stimulated by the findings that proteasomal inhibition could affect p53 
stabilization in the cells, it is interesting to know that whether this, in any way is 
linked to the autophagic induction in C1-treated cells. This is especially relevant 
according to a previous report highlighting a unique role brought about by p53 
inhibition which promotes autophagy (Tasdemir et al., 2008). In the said study, 
depletion, deletion or inhibition of p53 serves as a signal for autophagy progression. 
More importantly, inducers of autophagy, such as nutrient deprivation and rapamycin 
invariably caused p53 depletion. It is thus likely that C1 may act in a similar manner 
as these autophagic inducing agents. Indeed, induction of LC3II accumulation by C1 
was effectively blocked in cells pre-treated with MG132 (Figure 44). This data is 
negatively correlated with p53 status in the cells, and suggests correlative evidence 














        
                                                                                                                        
                       
 
Figure 44: Inhibition of proteasomal degradation impedes LC3II accumulation 
induced by C1. Following MG132 pre-treatment for 1 hour at 1.25 µM or 2.5 µM, 
cells were treated with or without C1 (100 µg/ml) for 18 hours. Total lysates were 
collected for Western blot assessments, and LC3II protein expression was observed 








4.12 Decrease in p53 protein expression and increase in LC3 lipidation are 
controlled by ERK signaling 
 The Ras-Raf-MEK-ERK signaling pathway was shown to be a regulatory 
factor for p53-Hdm2 auto-regulatory feedback loop (Phelps et al., 2005). The MEK 
kinase, which directly acts upstream of ERK, was suggested to play a homeostatic 
role in maintaining the balance between p53 and human double minute 2 (Hdm2)  by 
regulating the nuclear export of hdm2 mRNA, thereby suppressing p53-induced cell 
cycle arrest and apoptosis (Phelps et al., 2005). This study provides evidence that 
ERK signaling pathway may regulate p53 level in a completely opposite way. siRNA 
targeted against ERK2 effectively restored downregulation of p53 brought about by 
C1 treatment at 18 hours (Figure 45). In contrast, LC3II expression was effectively 
inhibited following ERK2 silencing (Figure 45). As the depletion of total p53 level is 
important for autophagy progression, and ERK2 activation is a potent signal for 
autophagy, these data are suggestive of an integral role mediated by ERK-induced 
















                 
 
Figure 45: Decrease in p53 protein expression and increase in LC3 lipidation 
are controlled by ERK signaling. Cells were being silenced with ERK2 or 
scrambled siRNA according to Materials & Methods, and allowed to recover for 48 
hours post transfection. Cells were then subjected to C1 treatment for 18 hours before 
being harvested and protein expression of p53, LC3II and ERK1/2 were analysed by 









1 Cell death pathways activated by C1 in HCT116 cells 
This is a report on a novel anti-cancer compound, C1, triggered cell death 
with hallmarks of apoptosis, and significantly inhibited clonogenic capacity of 
HCT116 cells.  Intriguingly, pre-treatment of cells with the pan-caspase inhibitor, 
zVAD-fmk, failed to rescue colony formation, despite blocking apoptotic features. 
Similarly, the necrosis inhibitor, necrostatin, had no effect of C1-induced cell death, 
thereby suggesting the existence of alternative cell death mechanism(s) in 
conjunction with apoptosis. Electron microscopic and biochemical analysis revealed 
a morphological phenotype consistent with autophagy. Of note, neither the 
pharmacological inhibition of apoptosis (zVAD-fmk) nor autophagy (3-MA) was 
able to salvage cells from the effect of C1, suggesting that both pathways were 
essential in the regulation of cell death. 
 
2 Autophagic signaling induced by C1 follows a non-canonical pathway 
The tumor suppressor protein Beclin1 has been shown to play a critical role in 
autophagy execution and its knockdown blocks autophagic cell death (Yue et al., 
2003).  However, using a model of neurotoxin-induced cell death, Zhu et al showed 
that the existence of autophagic vacuolizations was independent of Beclin1 (Zhu et 
al., 2007). Similarly, in a breast cancer cell model, the phytoalexin resveratrol was 
found to induce non-canonical autophagy, which was dependent on inhibition of 
mTOR signaling (Scarlatti et al., 2008). The data presented here clearly indicate that 
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gene silencing of Beclin1 neither inhibited autophagy nor rescued human cancer cells 
from C1-induced death. Although the functional relevance of autophagy as a cell 
survival response or a death execution mechanism is still being debated, recent 
evidence tends to favor the model whereby autophagy in the non-canonical settings is 
invariably associated with cell death (Scarlatti et al., 2008). Of note, Beclin1 
expression was significantly lower in tumor cells undergoing C1-induced autophagy, 
which begs the question whether this is a general feature of non-canonical autophagy 
or an unrelated event exclusive to this system. In addition to the redundancy of 
Beclin1, the requirement of the class III PI3 kinase was also questionable as 
inhibition of its activity by 3-MA did not significantly rescue autophagic phenotype 
in C1-treated cells. This is also in line with the observations reported with 
resveratrol-induced autophagy (Scarlatti et al., 2008).  Contrary to the effect of 
beclin1 knockdown, silencing of Ulk1 (homolog of yeast Atg 1) or Atg7 impeded 
autophagic signaling, thus proving that these two proteins remained as essential 
mediators even in non-classical autophagy. However, it remains to be determined 
whether the multi-protein complex in the vesicle nucleation step is still being formed, 
regardless of the redundancy of Beclin1 in C1-induced autophagy.   
 
3 Autophagy and apoptosis are independent of each other but controlled 
by upstream ROS production 
In several settings, autophagic signaling sets the stage for apoptosis to occur, 
while in others inhibition of autophagy triggers an apoptotic cell death program 
(Boya et al., 2005; Gonzalez-Polo et al., 2005). It was shown here that C1-induced 
 142
cell death could be orchestrated through multiple signals that are independent of each 
other. Although apoptosis inhibitors effectively blocked caspase-dependent cell 
death, there was virtually no effect of these inhibitors on the autophagic pathway. 
Reciprocally, gene silencing of Atg7 or Atg1 reduced the extent of autophagic 
induction, but apoptotic signaling remained unaffected.  While the downstream 
signaling for each pathway appears to be autonomous, the upstream trigger 
controlling the induction of each of these signals is an early increase in intracellular 
ROS production, which drives ERK and JNK activation.  
 
4 Photoactivation as a cancer treatment modality 
 This study focused on the biological activity of a photoactivated product, 
Merodantoin, or Compound 1 (C1). Previously, photoactivation was used as a 
treatment modality for certain cancers (Hsi et al., 1999). Photoactivation is a therapy 
in which certain bacteria, viruses and cancer cells are targetted to photoactive 
compounds and at the same time, exposure to light (Oleinick and Evans, 1998). This 
treatment modality was termed photodynamic therapy (PDT). However, with time, 
PDT was proven to be a cumbersome process as it requires simultaneous exposure of 
the biological system to both photoactivated compound and light (Gulliya et al., 
1990). Due to this limitation, PDT was only suitable for treatments of solid tumors 
and purging of bone marrow for transplantation (Hsi et al., 1999; Mulroney et al., 
1994). To circumvent this problem, our group had devised a process to preactivate 
the compound by exposure to light before it was used as a therapeutic agent (Gulliya 
et al., 1990). In this way, the biological activity of the compound can be separated 
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from the photoactivation process. This method of activation of photodynamic 
compound was then termed ‘preactivation’ (Pervaiz et al., 1993). 
 To test out the concept of preactivation, a lipophilic polymethine dye 
merocyanine 540 (MC540) was used as a test compound. MC540 was initially 
discovered as a photosensitizer which showed high selectivity for tumor cells, 
especially useful in killing lymphoma and leukemic cells (Easton et al., 1978; Sieber, 
1987). Preactivated MC540 (pMC540) was remarkably effective in targeting tumor 
cells, activating apoptosis in a variety of cancer cells while showing minimal toxicity 
in normal blood mononuclear cells (Gulliya and Pervaiz, 1989; Itoh et al., 1993; 
Sieber et al., 1987). In vivo, pMC540 was proven to be more effective than non-
preactivated MC540 compounds in prolonging the lifespan of L1210 leukemic mice 
(Pervaiz, 2001).  
 Though preactivation solved the limitations of PDT, pMC540 had a short 
storage limit of 30 days and was prone to degradation (Moan and Berg, 1991). The 
activity of pMC540 was also reduced drastically by 50% upon light exposure. In 
view of the fact that pMC540 is not a pure compound but contains a mixture of 
photoactivated products, our group set out to purify and identify the components of 
the preactivated compounds. Three pure products, as analyzed by mass spectrometry 
and NMR analysis were being extracted. These compounds were termed C1, C2 and 
C5 (Pervaiz et al., 1999b).  
 Further analysis of these compounds revealed that C1 and C2 were potent 
activators of the classical apoptotic pathways in promyelocytic leukemia cell line 
HL-60 (Pervaiz et al., 1999b). Cell death induced by these purified products was 
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exemplified by phosphatidylserine exposure, caspase-8 and -3 activation and 
cytosolic translocation of cytochrome c. Interestingly, C1-induced cytochrome c 
release was dependent on MOMP while C2 treatment did not result in MOMP and 
mitochondrial swelling, suggesting that the release of cytochrome c by C1 and C2 
were dependent on different mechanisms. 
 
5 Intracellular generation of H2O2 as a novel effector mechanism of cell 
death  
 It is now well established that the redox status and changes in intracellular 
milleu are important determinants of cell fate. It was previously documented that the 
activity of the purified photoactivated compound, C2 is dependent on its ability to 
generate intracellular H2O2 (Hirpara et al., 2001). Intriguingly, H2O2 production 
induced by C2 originated from the mitochondria. More importantly, mitochondrial-
derived H2O2 production subsequently resulted in intracellular acidification, which 
served as an effector mechanism for C2-induced apoptosis in HL-60 leukemic cells. 
In contrast, though C5 also induced cytochrome c release, it was unable to trigger 
cytosolic acidification and thus, elicited a marked reduced potency in caspase 
activation.  
 In search of a mechanistic explanation for cytosolic acidification, it was later 
discovered that H2O2 could act as an effector molecule in mediating Bax 
translocation in tumor cells (Ahmad et al., 2004b). By using either exogenous 
addition of H2O2 or drug-induced H2O2 production, H2O2-mediated cytosolic 
acidification was proven to be essential in the recruitment of mitochondrial pathway 
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in a variety of tumor cells (Ahmad et al., 2004b; Hirpara et al., 2001). Interestingly, 
in another study involving Resveratrol, the presence of low concentrations of 
Resveratrol reverted apoptotic hallmarks induced by anticancer drugs C2, vincristine 
or daunorubicin (Ahmad et al., 2004a). Low concentrations of Resveratrol resulted in 
elevation of intracellular O2
•ˉ dependent on the NADPH oxidase system, which 
blocked mitochondrial H2O2 production. Consequently, decreased intracellular H2O2 
levels also inhibited cytosolic acidification thereby resulting in a non-permissive 
environment for apoptotic signaling.  
 In addition, the ability of small molecular compounds to generate intracellular 
H2O2 was shown to be an effector mechanism in the sensitization of tumor cells to 
death receptor-mediated apoptosis. LY294002, a phosphotidylinositol-3-kinase 
(PI3K) inhibitor, and its inactive analog, LY303511, were found to sensitize tumor 
cells to drug-induced apoptosis by an elevation of intracellular H2O2 level in cervical 
carcinoma HeLa (Poh and Pervaiz, 2005). The increase in intracellular H2O2 level 
induced by these two compounds is independent of PI3K activity. In a neuroblastoma 
model, LY303511 was also found to be capable in sensitizing tumor cells to TRAIL-
induced apoptosis mediated by intracellular H2O2 generation (Shenoy et al., 2009). 
Notably, H2O2 elevation by the LY compound was an important signaling molecule 
in MAPK family members’ activation, leading to upregulation of death receptors and 
enhanced cell death response. 
 Apart from the activation of cell death by targeting the executioners of the 
cell death circuitry, apoptosis could also be achieved by downregulation of survival 
factors. The involvement of H2O2 in this setting was elegantly shown by 
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downregulation of protein kinase 2 (CK2), a serine/threonine kinase involved in cell 
growth and proliferation (Ahmad et al., 2006; Wang et al., 2006b). Chemical 
inhibition or antisense-mediated knockdown of CK2 elevates H2O2 production which 
sensitized ALVA-41 and PC-3 prostate cancer cells to apoptosis (Wang et al., 
2006a). 
 Collectively, these studies demonstrated a positive role for H2O2 in the 
modulation of cell death. Particularly, elevation of intracellular H2O2 level appears to 
be a common denominator in drug-induced apoptosis. The myriad ways of how H2O2 
could mediate apoptotic induction may contribute to its potency as an upstream 
mediator of cell death. 
 
6 Reactive oxygen species: A paradigm shift 
 As discussed previously in the Introduction section, the relationship between 
ROS and cell death is not always clear cut. Though it has been firmly established that 
high levels of ROS mediates cellular damage and apoptosis, in recent years there are 
emerging evidence to suggest a conflicting role of ROS with regard to oncogenesis. 
 The vast amount of evidence linking O2
•ˉ to growth and survival has led to a 
paradigm shift which involves a tight balance between O2
•ˉ and H2O2 in determining 
the cellular response (Pervaiz and Clement, 2002b). The ratio between H2O2 and O2
•ˉ 
is determined by the intracellular antioxidant defences and is maintained in a tightly 
regulated manner during normal homeostasis. A tilt of the balance to O2
•ˉ over H2O2 
favors cell survival by promoting cell proliferation or inhibiting apoptosis, thereby 
facilitating the process of tumorigenesis (Clement et al., 1998). In contrast, a slight 
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elevation of H2O2 with a concomitant decrease in O2
•ˉ level is prohibitive for 
oncogenesis by promoting the execution of apoptotic signals (Pervaiz and Clement, 
2002a; Pervaiz and Clement, 2002b). This is predominantly achieved via the effect of 
cytosolic acidification and suppression of O2
•ˉ accumulation. It is important to 
acknowledge that a slight tilt of the ratio between the two species is the key point of 
this theory; while in the case of overwhelming production of ROS, regardless of the 
species, will inadvertently be deleterious to the cells. 
 Currently, there is a huge body of evidence in support of the highly varied 
role of ROS in regulating cell metabolism. In particular, a mild elevation in O2
•ˉ level 
has been linked to cell proliferation and cell growth. This is mediated, in part, by the 
activity of O2
•ˉ in stimulating early growth-related genes such as c-jun and c-fos 
(Burdon, 1995). In addition, O2
•ˉ has also been linked to receptor tyrosine kinase 
(RTK) activation, which is a major proliferative signal involved in oncogenesis 
(Heffetz et al., 1990). Similarly, increase in O2
•ˉ was also found to be responsible for 
activation of transcription factors, such as AP-1 and NFκB, as well as in the 
activation of various ion channels such as Na+/H+ exchanger (NHE) membrane 
transport pumps (Droge, 2002; Sauer et al., 2001). The alterations in the intracellular 
O2
•ˉ level was invariably shown to lead to a mild “pro-oxidant” state in the cells, 
which is permissive for cell proliferation. 
 Interestingly, an increase in intracellular O2
•ˉ was shown to be critical in 
inducing the activity of Na+/H+ exchanger 1 (NHE1) gene promoter, leading to 
NHE1 expression, which strongly correlates to tumor cell’s resistance to apoptosis 
(Akram et al., 2006). In a separate study, inhibition of O2
•ˉ production overrode the 
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protection conferred by Bcl-2 and sensitized Bcl-2 over-expressing cells to drug-
induced apoptosis (Chen and Pervaiz, 2007). Along this line, Bcl-2 over-expression 
was able to generate a pro-oxidant state by constitutively increasing O2
•ˉ level in the 
cells leading to inhibition of cytosolic acidification. To further substantiate the role of 
O2
•ˉ in oncogenesis, constitutively active Rac-1 increased O2
•ˉ level and cytosolic 
pH, thereby conferring resistance of tumor cells to apoptosis (Pervaiz et al., 2001). 
Interestingly, treatment of cells with exogenous H2O2 concurrently led to a decrease 
in O2
•ˉ concentration accompanied by acidification of the intracellular milleu. 
 On the flip side, augmentation in intracellular O2
•ˉ level was also shown to be 
inhibitory for apoptosis. Over-expression of Cu/Zn SOD, which led to reduction of 
intracellular O2
•ˉ level, increased the sensitivity of tumor cells to chemotherapeutic 
drugs (Saito et al., 2003). The reverse experiment with SOD inhibitor, 
diethyldithiocarbamate (DDC), elevated O2
•ˉ concentration in the cells and reduced 
the extent of cell death induced by anti-cancer agents (Clement and Stamenkovic, 
1996). Similarly, O2
•ˉ elevation in M14 melanoma cells inhibited drug-induced 
apoptosis by decreasing the activity of caspase-3 (Pervaiz et al., 1999a).  
  
7 C1-induced ROS production is a signal for autophagy and apoptosis 
 The premise of this thesis centres on the ability of the small molecule 
compound, C1 in generating ROS as an intracellular messenger. In the current model, 
the outburst of ROS production occurred in a very early setting, within 15 minutes of 
incubation with C1. Utilizing a mitochondrial O2
•ˉ specific probe, O2
•ˉ was detected 
as one of the ROS species being produced. The burst of O2
•ˉ production increased 
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with time, which peaked at 1 hour time point and subsequently decreased over time. 
Similarly, ROS level was also significantly higher upon short time points of C1 
incubation, from 15 minutes to 3 hours, as labeled by CM-DCFHDA and detected by 
flow cytometric analysis. Importantly, utilization of H2O2-specific scavengers, 
catalase and transient over-expression of the catalase gene confirmed the role of 
H2O2 in this model. 
 An interesting question which arises from these observations is the 
proportional contribution of these ROS species in the signaling of C1-activated 
pathways. In view of the fact that O2
•ˉ detected in this model originated from the 
mitochondria, it is highly unlikely that O2
•ˉ, being a charged molecule, could 
efficiently translocate from the mitochondria to the cytosol and activate the 
downstream effectors, such as ERK and JNK, which are predominantly cytosolic 
proteins in their inactive form. O2
•ˉ generated from the mitochondrial electron 
transport chain is mainly released into the matrix, with a small proportion being 
released into the intermembrane space (Turrens, 2003). It is widely acknowledged 
that most of the O2
•ˉ being produced in the mitochondria undergoes dismutation 
reaction to H2O2 via the action of MnSOD (Halliwell B, 2007). Furthermore, the 
rapid decrease in O2
•ˉ level may suggest a heightened SOD activity in HCT116 cells. 
Therefore, it is most probable that H2O2 generated from O2
•ˉ dismutation was being 
translocated from the mitochondria to the cytosol. This is due to the fact that H2O2 
could freely transverse membranes. That being said, it remained possible that the 
source of H2O2 produced by C1 is generated by other enzyme systems, such as 
xanthine oxidase and monoamine oxidase.  
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8 ROS is a critical signal for the activation of Map Kinases  
 This study highlighted the role of ROS by demonstrating its ability to activate 
two members of the MAP kinase family, JNK and ERK. Indeed, generation of ROS 
induced by C1 could be effectively scavenged by exogenous addition or transient 
overexpression of catalase, strongly suggesting an involvement of H2O2 in the current 
model. The identification of ROS production is an important component in this work 
mainly due to the fact that ROS signaling eventually resulted in the activation of 
MAPKs, specifically ERK and JNK kinases, which are central to C1-induced 
autophagy and apoptotic cell death.  
 Oxidative stress has been associated with MAPK through various 
mechanisms. Oxidative stress-induced ERK kinase signaling has been documented in 
a variety of cell lines including hepatocytes, cardiomyocytes, fibroblast, smooth 
muscles and epithelial cells (Blanc et al., 2003; Buder-Hoffmann et al., 2001; Conde 
de la Rosa et al., 2006; Kim et al., 2001; Xiao et al., 2002). In addition, the myriad 
ways of how ROS could lead to ERK activation provide substantial insights on the 
significance of this pathway. It appears that during most circumstances, ERK 
activation by free radicals is mediated by an upstream effector involved in ERK 
signaling pathway. For instance, ROS could enhance epidermal growth factor (EGF) 
signaling by inducing EGF receptor phosphorylation and downstream activation of 
the Ras-RAF-MEK-ERK signaling pathway (Knebel et al., 1996). In addition, 
platelet-derived growth factor (PDGF) receptor and SRC kinases are known targets 
of oxidative stress, and are both capable of activating ERK (Knebel et al., 1996; Zou 
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et al., 1996). Moreover, nitric oxide may lead to ERK activation by causing 
nitrosylation of a critical cysteine residue in Ras protein (Lander et al., 1996). 
Pharmacological inhibitors of MEK1 and MEK2, such as U0126 and PD98059 
effectively inhibited ROS-induced ERK activation, rendering evidence that ROS acts 
via upstream mediators of ERK in inducing ERK activation (Lee et al., 2006; Lee et 
al., 2005). Interestingly, the data presented here coincide with these observations as 
pre-incubation of PD98059 completely abolished the extent of ERK phosphorylation 
induced by C1. 
 On the other hand, JNK activation was also shown to be mediated by various 
oxidants and ROS-inducing drugs including H2O2, arsenite trioxide, UV radiation 
and cadmium chloride (Conde de la Rosa et al., 2006; Dent et al., 2003; Leonard et 
al., 2004; Meier et al., 1996). Similar to ERK, a surge in JNK activity induced by 
ROS could be mediated by upstream modulators in the MAP kinase signaling 
pathway. Apoptosis signal-regulating kinase 1 (ASK1) is a MAPKKK which 
mediates the activation of JNK and p38 Map kinases (Ueda et al., 2002). ASK1 is in 
turn regulated by the binding of reduced thioredoxin during normal states which, 
upon oxidative stress, becomes oxidized and dissociated from ASK1 (Saitoh et al., 
1998). The critical role of ASK1 in ROS-mediated apoptosis has been shown in both 
in vitro and in vivo settings (Yasinska et al., 2004). Mouse embryonic fibroblasts 
(MEFs) deficient in ASK1 activity was shown to be more resistant to oxidative 
stress-induced apoptosis while exhibiting a significantly lower level of JNK 
activation as compared to wild type MEFs (Matsukawa et al., 2004; Matsuzawa et 
al., 2002). One of the most potent activator of ASK1 is H2O2, and H2O2 production is 
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the mechanism of activation for various anti-cancer drugs in the regulation of ASK1-
mediated cell death (Goldman et al., 2004; Machino et al., 2003; Tobiume et al., 
2001). In this study, though the upstream mediator involved ROS-induced JNK 
activation is not known, ASK1 remained a highly probable target of ROS. Moreover, 
H2O2 was identified as one of the major species responsible for C1-induced cell 
death. ASK1 could represent a possible link between ROS and JNK activation, 
leading to downstream cellular responses. 
 To conclusively delineate the pathways involved in the anti-tumor activity of 
C1, ROS scavengers and transient over-expression of catalase were utilized in this 
study. Robust activation of ERK and JNK were dramatically reduced following 
inhibition of ROS production, indicating that ROS is the upstream mediator of 
MAPKs activation in this system.  
 Previously, various studies have demonstrated the role of inactivating 
phosphatases in the regulation of Map kinases. OH• could lead to attenuation of the 
MKP activity, thereby resulting in a surge in ERK activity (Whisler et al., 1995). In 
another model involving TNF-α- induced cell death, MKPs oxidation mediated by 
H2O2 was identified as the main mechanism of JNK-mediated cell death (Kamata et 
al., 2005). While the treatment of HCT116 cells by C1 also led to a reduction in 
MKP1 protein level, it remained to be investigated whether oxidation of MKPs is 





9 The role of ROS in modulating cell death: Involvement of ERK and JNK 
 The earlier part of the Discussion section had illustrated the myriad ways of 
utilizing ROS as an effector mechanism in inducing MAPKs activation. While the 
connection between ROS and MAPKs activation had been extensively studied, more 
importantly the physiological outcomes of their interaction need to be deciphered.  
 The effects of ROS production in carcinogenesis are manifested in many 
ways, depending on the stimulus and the rate of ROS production. ROS could play a 
stimulatory role in oncogenesis, and this is mainly propagated through ROS-
stimulation of the Ras-Raf-Mek-ERK pathway (Jiang et al., 2005). One of the 
downstream targets of this pathway is the transcription factor promoter specificity 
protein 1 (Sp1), which has been shown to be phosphorylated by ERK (Yagoda et al., 
2007). Following its activation, Sp1 mediates the upregulation of vascular 
endothelial growth factor (VEGF) which, in turn, contributes to angiogenesis (Banan 
et al., 2001). In addition to this, the Ras signaling pathway also contributes to 
oncogenesis by activation of the PI3 kinase- Akt axis, the major survival factors in 
the cells (Shelton et al., 2004; von Gise et al., 2001).  
 In contrast to the widely known cancer promoting effects in oxidative stress-
induced Ras-ERK signaling pathway, a tumor suppression role of ROS has also been 
reported. In these settings it is generally believed that the anti-tumor activity of ROS 
is attributed to its ability to engage JNK and p38 signaling pathways with the 
eventual execution of apoptosis. The p38 Map kinase pathway negatively regulates 
tumorigenesis by its activating role in replicative senescence, contact inhibition, 
DNA damage responses and apoptosis (Han and Sun, 2007; Ren et al., 2009). In the 
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current study, the presence of p38 is ruled out as its activation was not significantly 
observed in C1-treated cells. In contrast, ROS-induced JNK activation turned out to 
be an important signaling mechanism in the modulation of cell death.  In addition, 
abrogation of ROS production by exogenous ROS scavengers and catalase over-
expression protected HCT116 cells against C1-induced cell death. A large body of 
evidence in the literature is in line with this finding. In a study utilizing pancreatic 
beta cells, synergistic activation of JNK was triggered by TNF-α and interferon 
gamma (IFN-gamma), and apoptosis induced in this system is dependent on JNK-
mediated p53 activation (Kim et al., 2005a). In exploring mechanisms of ROS 
accumulation-induced cell death, the apoptotic response was further amplified by c-
FLIP downregulation, accompanied by prolonged JNK activation (Nakajima et al., 
2008). H2O2- induced non-apoptotic cell death was mediated by JNK1 via its 
regulation on PARP-1 activation and phosphorylation (Zhang et al., 2007). 
Evidence presented here suggested that ROS-mediated JNK activation is in 
line with the current literature in its ability to induce apoptosis. On the other hand, 
although ROS-mediated ERK activation has often been linked to transformation and 
malignancy, the data in this study clearly showed otherwise. This study demonstrated 
a crucial role of ROS in modulating the ERK-mediated cell death pathway. 
Activation of ERK demonstrated an anti-tumor role of ROS which positively 
regulates cell death.  
 
10 ROS controls autophagic signals through MAPK 
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Classically, autophagy is described as a cellular clearance mechanism to 
remove damaged organelles and protein aggregates and thus serves as a 
cytoprotective mechanism to counteract oxidative stress in cells (Levine, 2005). In 
yeast, mitophagy occurs as a response to nitrogen starvation and is mediated through 
a regulator of oxidative stress, Uth1 gene (Kissova et al., 2004). On the other hand, 
reports have also shown that ROS could serve as signaling molecules that directly or 
indirectly activate autophagy. To that end, it has been shown that induction of 
autophagy resulted in selective degradation of catalase, leading to accumulation of 
mitochondrial ROS and ultimately cell death (Yu et al., 2006).  In a separate study, 
TNF-α was shown to increase the expression of Beclin1 by a ROS-dependent 
mechanism (Djavaheri-Mergny et al., 2006). By using mitochondrial electron 
transport chain inhibitors, Chen et al demonstrated the importance of mitochondrial 
ROS in the regulation of autophagic cell death. The existence of autophagic cell 
death in transformed and cancer cell lines was salvaged by the presence of tiron and 
over-expression of SOD2, indicating a role of O2
•ˉ to act as a second messenger in 
autophagic signaling (Chen et al., 2007). The findings reported here lend support to 
these observations by demonstrating the involvement of mitochondrial-derived ROS 
in C1-induced autophagy, as well as the inhibitory effect of H2O2 scavenger, catalase. 
To provide a link between C1-induced ROS production and autophagy, its ability to 
activate two members of the MAP kinase family, JNK and ERK, was highlighted. 
Indeed, generation of ROS induced by C1 could be effectively scavenged by 
exogenous addition or transient overexpression of catalase, strongly pointing to the 
involvement of H2O2 in the current model. Furthermore, LC3II accumulation could 
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also be abolished through the exogenous addition of or transient transfection with 
human catalase, suggesting a major signaling role of H2O2 in autophagy. This is 
consistent with a previous report on TNF-α induced accumulation of H2O2, which 
was shown to be responsible for autophagic cell death (Djavaheri-Mergny et al., 
2006). Indeed, H2O2 was also found to be an important mediator in starvation-
induced autophagy, through its activity in regulating Atg4 protease (Scherz-Shouval 
et al., 2007). Post-translational modification of Atg4 by oxidation greatly enhanced 
autophagosome formation in starvation-induced autophagy (Scherz-Shouval et al., 
2007). H2O2 and ROS-inducing agents, 2-methoxyestradiol (2-ME) was shown to 
trigger autophagic cell death in transformed and cancer cell lines, while it failed to 
induce autophagy in non-transformed cells (Chen et al., 2008). Therefore, it appears 
that redox-regulation of autophagy is largely dependent on the magnitude and the 
rate of ROS accumulation. Whether ROS involvement in autophagy represents a 
general mechanism in autophagic induction remains to be investigated. Nevertheless, 
this study highlighted the novel role of ROS in mediating MAPK activation, 
specifically in the signaling of ERK and JNK kinase pathways in the modulation of 
autophagy. 
  
11 ERK is a major mediator in C1-induced signaling pathways 
 This study reported the importance of the ERK signaling cascade in 
mediating C1-induced autophagy and apoptosis. Of note, ERK activation occurred in 
a transient manner. It was activated rapidly within a short span (30 minutes) of C1 
incubation, and the extent of ERK phosphorylation increased with time, peaked at 3 
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hours before it was gradually reduced. Despite the fact that ERK phosphorylation did 
not occur in a sustained and prolonged manner, ERK activation was able to exert 
important biological functions in the modulation of two critical physiological 
processes. It would be interesting to investigate further on the relationship between 
this mode of transient ERK activation and the biological impacts it transmits, if there 
is any. Furthermore, the ability of the MEK inhibitor, PD98059 to inhibit 
phosphorylation of ERK revealed that ERK activation by C1 was dependent on the 
sequential activation of the ERK signaling module, and suggested that ERK was not 
a direct target of ROS in this system. In the next section, the role played by ERK in 
controlling two different axes of cellular modalities, namely autophagy and 
apoptosis, will be discussed in detail. 
 
12 Modulation of apoptosis by ERK signaling 
 A general dogma surrounding the MAPK signaling cascade entails that ERK 
activation is associated with cell survival, whereas JNK and p38 control cell death. 
This dichotomy arises from the large body of data linking ERK activation to Ras-
induced transformation, cell proliferation and cell cycle progression (Dhillon et al., 
2007). This is no doubt an oversimplification on the roles of MAPKs, as the cell fate 
upon extracellular stimulus often depends on cell type and the specific cellular 
context.  
 With regard to the activation of cell death by C1, ERK activation was found 
to be indispensable. Inhibition of ERK phosphorylation by PD98059 virtually 
completely blocked various hallmarks of apoptosis. Furthermore, pharmacological 
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inhibition of ERK also impaired cytochrome c and Bax translocation, suggesting that 
the mitochondrial pathway could be a major target of ERK activation. More 
importantly, PD98059 treatment conferred significant protection against C1-induced 
reduction of colony formation, which underscored the tremendous implication for 
ERK as a novel target for anti-tumor therapy. Notably, gene-mediated silencing of 
ERK further corroborated the inhibitor studies, and highlighted the critical 
involvement of both ERK1 and ERK2 in the modulation of apoptosis.  
 In addition to HCT116 cells, the metastatic breast cancer cell line MDA-MB-
231 was also sensitive to inhibition of ERK. Serendipitously, both HCT116 and 
MDA-MB-231 cells harbour oncogenic K-Ras mutation. In contrast, MCF-7, which 
is a non-metastatic breast cancer cell line with normal Ras status, is refractory to 
PD98059 treatment. These results suggested a possible link between Ras status and 
sensitivity of cells to ERK activation. Furthermore, activating mutation of K-Ras is 
associated with 30% of human cancers, including colorectal carcinomas (Andreyev et 
al., 2001; Schubbert et al., 2007). It is thus promising that ERK activation by ROS-
dependent mechanisms in these Ras oncogene- transformed cells could specifically 
target these tumors to self destruction by activating their intrinsic programmed cell 
death. 
 Interestingly, activation of cell death by C1 is associated with a transient 
activation profile of ERK. On the other hand, oncogenic transformation and 
accelerated proliferation induced by ERK has been shown to be dependent on a 
constitutively activated signal of ERK (Oka et al., 1995). This is partly mediated 
through the promoting effects of ERK on cell cycle progression (Pages et al., 1993). 
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It remains a possible hypothesis that the transient activation of ERK induced by C1 
precludes the possibility of prolonged oncogenic induction, but is sufficient to 
activate cell death machineries for efficient apoptotic execution. Nevertheless, the 
feasibility of this proposal would need to be substantiated with more conclusive 
experimental evidences. 
 
13 Modulation of autophagy by ERK signaling 
Although the advancement in autophagy research has accelerated in recent 
years, the involvement of ERK in this field has not been studied in great depths. In 
particular, the mechanisms of ERK involvement in autophagy have not been 
extensively studied. Most of the studies in the current literature have pointed to a 
positive regulatory role of ERK in autophagy, though there are other studies which 
contradict this role. In a neuroblastoma model, ERK 1/2 activation was reported to be 
critical in neurotoxin-induced autophagic cell death (Zhu et al., 2007). The activity of 
ERK and JNK were also found to be important in TNF-α induced apoptotic and 
autophagic cell death in L929 cells (Cheng et al., 2008). Curcumin, a natural 
compound, induces autophagic cell death in an ERK-dependent manner (Aoki et al., 
2007). These studies have established a causal relationship between ERK activation 
and autophagy. However, in contrast to the interplay between JNK and autophagy, 
the exact role of ERK in autophagy has not been clearly defined. In this study, the 
association of ERK in autophagy was firmly established. Pharmacological inhibition 
of ERK almost completely abrogated the autophagic response triggered by C1, as 
determined by LC3II accumulation and EM analysis, implicating ERK in the 
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induction of autophagy. Genetic silencing of ERK also corroborated the inhibitor 
studies, further confirming a positive regulatory role of ERK in the induction of 
autophagy. Serendipitously, only ERK2 silencing could abrogate C1-induced LC3 
expression, excluding the role of ERK1 in controlling autophagy. This specificity in 
controlling autophagy indicated that, at least with regard to C1-induced autophagy, 
ERK1 and ERK2 are not exactly functionally redundant. This is consistent with a 
recent study on the mechanism of ERK2 localization to the mitochondria which was 
indispensable for mitophagy and autophagic cell death (Dagda et al., 2008). To date, 
it is as yet unclear as to whether the association of ERK activation with autophagy is 
a function of its ability to activate downstream transcription factors or an extra-
nuclear function of ERK. This study provided new insights into the molecular 
mechanisms of ERK-induced autophagy by identifying an association between ERK 
and p53. Previously, degradation of p53 was linked to an increased autophagic 
response, and p53 was suggested be a repressor of autophagy (Tasdemir et al., 2008). 
Here, a more upstream mechanism was identified in the heightened interest of p53-
mediated suppression of autophagy. C1 activation mediated a decrease in p53 protein 
expression, indicating redundancy of p53 in C1-induced cell death. Silencing of 
ERK2, which inhibited autophagy, also attenuated p53 downregulation. In addition, 
p53 level was restored by inhibition of proteasomal degradation. Similarly, 
proteasome inhibitors also decreased the extent of autophagy in C1-treated cells. 
Taken together, these data suggested that the activation of autophagy by C1 was in 
part, due to ERK activation and subsequent ERK-mediated p53 degradation by the 
proteosomal degradation pathway.  
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14 Targeting the ERK signaling pathway for cancer therapy 
 Over the years, the ERK signaling cascade has gained prominent interest as 
attractive targets for cancer therapy, due to the critical involvement of its components 
in the regulation of cell proliferation and tumor progression. Virtually all, if not most 
of the key components of the ERK MAPK pathway have been found to be either 
overexpressed in human cancers or have been identified as putative oncogenes. 
Receptor tyrosine kinases (RTK), which includes members such as epidermal growth 
factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), is 
one of the most upstream signal which activates the Ras-Raf-MEK-ERK signaling 
module. EGFR was found to be mutationally activated in many tumors (Baselga and 
Arteaga, 2005), and developments of monoclonal antibodies and small molecule 
inhibitors against aberrant hyperactivated EGFR are currently underway (Roberts and 
Der, 2007), with some of them already in clinical use for the treatment of EGFR-
detectable cancers.  
 Downstream of the receptor tyrosine kinase pathway, aberrant Ras signaling 
has also been detected in multiple malignancies. Ras has been proposed to be 
mutated in 30% of human cancers, with high prevalence in lung and colon cancers 
(Malumbres and Barbacid, 2003). In addition, germline mutations and genetic 
alterations of Raf have also lend credence to the efforts devoted into the inhibition of 
this particular pathway (Davies et al., 2002). 
 The findings generated from this study, however, cautioned against an over-
simplified approach in devising ERK signaling pathway as target-based therapies. 
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This study demonstrates that instead of propagating cell death, MEK inhibitors could 
be potent death suppressors. This observation suggests a novel feature of ERK away 
from its conventional dogma of anti-death and pro-survival roles. In particular, 
evidence presented here supports the notion that ROS-mediated ERK signaling could 
represent an attractive chemotherapeutic approach for cancer elimination, especially 
relevant to highly metastatic cancers harbouring oncogenic Ras mutations. 
Nevertheless, this study adds complexities to the seemingly straightforward 
properties of ERK-related therapies in cancer and suggests that any target based 
therapies should be carefully examined before its procession.  
 
15 Kinetics of JNK activation could determine the sensitivity of tumor cells 
to apoptosis 
 JNK activity alone may not be sufficient to determine the cell death response. 
It has been suggested that kinetics of JNK activation play a role in determining its 
biological function. Transient and modest JNK activation is required for liver 
regeneration (Schwabe et al., 2003), while sustained JNK activation caused by 
cytotoxic drugs or cellular insults has been shown to trigger apoptosis (Lin, 2003). 
Inhibition of dual specificity phosphatases, the MKPs, via oxidation of the critical 
cysteine residues by ROS, resulted in sustained JNK activation which was 
responsible for apoptotic cell death (Kamata et al., 2005). In contrast, NFκB could 
prevent sustained JNK activation via upregulation of ferritin heavy chain, a primary 
iron storage factor in the cells, leading to attenuated apoptosis (Pham et al., 2004). 
The data presented here is in agreement with recent reports highlighting the 
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importance of temporal activation of JNK in inducing apoptosis. In this study, 
sustained JNK activation was demonstrated following C1 incubation. A time kinetics 
analysis revealed that, although JNK phosphorylation was triggered almost 
immediately, within 30 minutes of drug treatment, the activation profile persisted 
throughout the time course of analysis. Correspondingly, MKP1 protein level was 
significantly downregulated at the time points when JNK phosphorylation was 
detected. It is hitherto unclear as to how different ROS levels could augment the 
extent and duration of JNK activation. Possibly, low levels of ROS production did 
not alter the MKP activity sufficiently resulting in transient JNK activation. In 
contrast, higher levels of ROS or a specific type of ROS is more efficient in 
mediating inhibition of MKP activity, leading to sustained JNK activation and 
apoptosis (McCubrey et al., 2006). In a separate study, c-FLIP downregulation was 
proposed as the mechanism responsible for prolonged JNK activation (Nakajima et 
al., 2008). This observation was also consistent with cleavage of MEKK1 in c-FLIP 
knockdown cells, providing an explanatory mechanism for prolonged JNK 
activation. 
 
16 Modulation of Apoptosis by JNK signaling 
 The involvement of MAPKs in apoptosis have been demonstrated in a variety 
of model systems including cytokines activation, oxidative stress and radiation (Bode 
and Dong, 2003; Kyriakis and Avruch, 2001; Rincon et al., 2001). Apart from 
transcriptional activation of c-Jun leading to induction of apoptotic genes such as 
Fas-L (Faris et al., 1998), a transcriptional independent role of JNK in apoptosis has 
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also been documented. This is largely documented via phosphorylation of pro or anti-
apoptotic proteins such as p53 and Bcl-2 (Maundrell et al., 1997; Milne et al., 1995). 
In this study, inhibition of JNK activation also attenuates apoptotic cell death. This 
was shown by inhibition of sub-G1 population, colony formation and cell death by a 
JNK inhibitor as well as by siRNA directed against JNK. Thus, we provide evidence 
that JNK represents an important mediator in controlling the apoptotic signaling 
cascade. Interestingly, it has been shown that JNK phosphorylation of Bcl-2 serves to 
promote autophagy and cell survival during early time points while delayed 
activation of JNK is a signal for apoptosis to occur (Wei et al., 2008b). In accordance 
with these findings, our findings demonstrate sustained and prolonged JNK 
activation, which may account for the differential cellular response brought about by 
C1. It is likely that early JNK activation signals for autophagy as an adaptive 
response to cellular stress while at the later time point, when the cells are 
overwhelmed by cytotoxic stimuli, JNK activation serves to switch the cells towards 
apoptotic cell death. 
 
17 Modulation of autophagy by JNK signaling 
 In this thesis the integral role of the Map kinases, ERK and JNK in mediating 
autophagy was highlighted. Activation of the JNK signaling pathway by ROS 
represents a novel mechanism of autophagic induction. Inhibition of JNK by its 
pharmacological inhibitor, SP600125, resulted in the reduction of LC3II protein 
expression. By gene-mediated knock-down experiments, JNK was found to be 
crucial for the regulation of C1-induced autophagy and apoptosis. Previously, JNK1 
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activity was demonstrated to be the key factor in starvation-induced autophagy, 
through phosphorylation of Bcl-2 and displacement of the Beclin1-Bcl-2 complex 
(Wei et al., 2008a). In contrast, this study did not implicate JNK1 in both autophagy 
and apoptosis, adding evidence to the JNK1/2 isoform specific roles in mediating 
cellular response (Bogoyevitch, 2006). It is hitherto unclear as to the cause of this 
disparity brought about by different JNK isoforms; however, it is apparent that the 
mode of actions and the effect of autophagic induction mediated by the different JNK 
isoforms were in stark contrast. To begin with, the extent of autophagic induction via 
drug-induced autophagy and starvation mediated autophagy may not be of the same 
magnitude. In addition, induction of c-Jun phosphorylation was found to be 
dependent on JNK activity. Moreover, pre-treatment of cells with cyclohexamide and 
actinomycin D reverted the increase in LC3II accumulation in C1-treated cells, 
indicating that the increased accumulation of LC3II might involve protein synthesis. 
A novel mechanism for JNK in autophagy was demonstrated in this study by 
showing that JNK inhibition could effectively augment Atg7 expression. This 
implies that autophagy-inducing activity of JNK was due to induction of the crucial 
mediator in autophagosome formation. Collectively, these data indicated that the 
regulation of autophagy by JNK could implicate the transcriptional activity of c-Jun. 
 JNK has been implicated in various models of autophagy in response to 
serum starvation, cytokines, growth factor withdrawal and neurotoxic drugs (Borsello 
et al., 2003; Jia et al., 2006; Li et al., 2006; Wei et al., 2008a). The myriad ways of 
JNK induction in autophagy may indicate that JNK is a core component in the 




This is a novel report describing the ability of a small molecule compound to 
simultaneously activate autophagic as well as apoptotic signaling pathways in the 
same cell, and where autophagy appears to be fueling rather than abetting death 
signaling.  Interestingly, the fact that this small molecule compound functions in a 
manner independent of Beclin1, further testifies to its therapeutic potential in the 
clinical settings where the tumor suppressor Beclin1 is non functional or down-
regulated. In contrast, the involvement of two critical Atg genes, Atg7 and Ulk-1 was 
integral in C1-induced autophagy. This unique cell death odyssey of tumor cells, i.e., 
simultaneous autophagy and apoptosis, is not restricted to a particular cell type as 
evidenced by the induction of autophagy in a variety of tumor cell types. 
Furthermore, our work highlights the critical involvement of early ROS production 
and downstream ERK and JNK activation in the dual signaling triggered by C1. ROS 
represents a central initiator of the C1-elicited cellular signaling pathway, which 
kick-starts the autophagy and apoptosis process by simultaneously activating two 
critical members of the Map kinase family, ERK and JNK. A novel function of JNK 
in autophagy was linked to its involvement in the regulation of Atg7 expression. 
Similarly, ERK may constitute a major initiator of autophagy by mediating p53 
degradation, though further studies are required to delineate the role of ERK in 
autophagy. While JNK inhibition appears to be sufficient to suppress the death 
signals, ERK was found to be a greater factor in the determinacy of life and death. 
This is most intriguing in view of the fact that the ERK signaling pathway has been 
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largely associated with oncogenesis and cellular transformation. Suppression of ERK 
activity almost completely abolished cell death hallmarks, suggesting that ERK is a 
major pathway which integrates the signals transmitted by ROS. The data also 
implicate ERK in mediating the intrinsic mitochondrial pathway which could further 
amplify the death signals. The potency of ERK as a cell death mediator is not limited 
to one cell lineage and, more importantly, ERK was shown to be critical in cell 
lineages with active Ras mutation. These data portrayed a novel role of ERK in the 
modulation of cell fate. While ERK activation normally contributes to proliferation 
and malignancy, on the flip side ROS-mediated ERK stimulation could specifically 
target oncogenic Ras-associated tumor cells, placing ERK as an attractive target for 
circumventing highly malignant cancers. In addition, this study underscores the 
feasibility of ERK and JNK as novel targets of cancer therapy. Taken together, these 
data underscore the tremendous potential of this small molecule compound for 
enhancing our understanding of the intricate complexities between different networks 
of cell death, as well as for the therapeutic induction of cell death in tumors that are 
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